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Abstract 
Atrial fibrillation (AF) is a disorder of the rhythm of electrical activation of the cardiac atria. It is the most common 
cardiac arrhythmia, has multiple aetiologies, and increases the risk of death from stroke. Pharmacological therapy is the 
mainstay of treatment for AF, but currently available anti-arrhythmic drugs have limited efficacy and safety. An 
improved understanding of how anti-arrhythmic drugs affect the electrophysiological mechanisms of AF initiation and 
maintenance, in the setting of the different cardiac diseases that predispose to AF, is therefore required. A variety of 
animal models of AF has been developed, to represent and control the pathophysiological causes and risk factors of 
AF, and to permit the measurement of detailed and invasive parameters relating to the associated electrophysiological 
mechanisms of AF. The purpose of this review is to examine, consolidate and compare available relevant data on in-
vivo electrophysiological mechanisms of AF suppression by currently approved and investigational anti-arrhythmic 
drugs in such models. These include the Vaughan Williams class I-IV drugs, namely Na+ channel blockers, β-
adrenoceptor antagonists, action potential prolonging drugs, and Ca2+ channel blockers; the “upstream therapies”, e.g., 
angiotensin converting enzyme inhibitors, statins and fish oils; and a variety of investigational drugs such as “atrial-
selective” multiple ion channel blockers, gap junction-enhancers, and intracellular Ca2+-handling modulators. It is 
hoped that this will help to clarify the main electrophysiological mechanisms of action of different and related drug 
types in different disease settings, and the likely clinical significance and potential future exploitation of such 
mechanisms. 
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1. Introduction 
Atrial fibrillation (AF) is a disturbance of the normally rhythmical beating of the cardiac atria, characterised by rapid 
(e.g., 400-600 beats/minute), irregular electrical and mechanical activation of the atrial muscle. It is the most common 
cardiac arrhythmia encountered in clinical practice, and has multiple causes, such as coronary artery disease, heart failure, 
valve disease and hypertension. Patients with AF have an increased risk of death from stroke, due to embolisation of 
atrial thrombi which form because the rapid and irregular activation causes uncoordinated atrial contraction and hence 
disturbed and reduced atrial blood flow. AF can be treated with electrical cardioversion, tissue ablation, and 
pharmacological therapy; the latter being the mainstay, particularly in the expanding elderly population. However, 
currently available anti-arrhythmic drugs are only moderately effective in preventing or terminating AF or maintaining 
sinus rhythm after it is restored, and may also exert adverse effects such as ventricular pro-arrhythmia, organ toxicity, or 
both (Camm et al., 2010). 
 Therefore, there is a major unmet need to develop more effective and safe drugs to control the atrial rhythm in 
patients with AF. This necessitates a drive towards an improved understanding of the various and complex mechanisms 
by which anti-arrhythmic drugs affect the electrophysiological mechanisms of AF initiation and maintenance, in the 
setting of the different cardiac pathologies underlying the arrhythmia. An essential part of this is to study patients in the 
clinic, and their isolated atrial tissues and cells, where possible. However, such studies are usually limited by 
confounding influences of multiple variables such as patient age, sex, disease history and drug treatments, and also by the 
difficulty or inability to measure required electrophysiological parameters from human hearts in-vivo. For this reason, 
various in-vivo animal models of AF have been developed to permit the necessary control over physiological and 
pathophysiological variables in different disease states in isolation, and also the continuous measurement of detailed and 
invasive parameters relating to the associated electrophysiological mechanisms of AF. 
 The purpose of this review is to examine, consolidate and compare available relevant data on in-vivo 
electrophysiological mechanisms of AF suppression by currently and previously approved, and investigational, anti-
arrhythmic drugs in such models. The focus, therefore, is on studies of atrium in in-vivo animal models. However, 
clinical electrophysiological data are utilised where available, and relevant in-vitro studies, including of ventricle, are 
incorporated where in-vivo data are lacking. For evaluation of clinical trials of current pharmacological and non-
pharmacological interventions, the reader is directed to current European (Camm et al., 2010) and American (Fuster et 
al., 2006; Wann et al., 2011) guidelines for the management of patients with AF. Details of molecular mechanisms of 
many of the anti-arrhythmic drugs are found in (Ravens, 2010). It is hoped that this review will help to clarify the main 
in-vivo electrophysiological mechanisms of action of different drug types in different disease settings, and the likely 
clinical significance and potential future exploitation of such mechanisms. 
 
 
2. Electrophysiological mechanisms of AF and implications for drug actions 
A variety of electrophysiological mechanisms of arrhythmia, reentrant and non-reentrant, likely initiates and maintains 
AF (Figure 1). Which of these mechanisms predominate in patients and animal models of AF depends partly on the 
underlying myocardial disease, because of disease-specific patterns of atrial electrical and structural changes, including 
long term remodelling (Workman et al., 2008). The clinical spectrum of AF ranges from paroxysmal (self-terminating 
episodes) to persistent (lasting >7 days) to permanent (pharmacologically and electrically inconvertible). The majority of 
atrial premature beats that initiate AF in patients originate from focal ectopic activity in or near the pulmonary veins, 
which may be either micro-reentrant or non-reentrant (Haissaguerre et al., 1998). Subsequent progression to persistent or 
permanent AF likely reflects the time-course and types of the atrial remodelling which, by their effects on the arrhythmia 
mechanisms, are expected to influence also the efficacy of pharmacological therapy.  
 
2.1. Reentry 
Reentry is rapid circuitous myocardial activation by an action potential wavefront as it continuously circulates a region of 
conduction block, re-exciting previously refractory tissue. This region of conduction block may be functional, i.e., a 
patch of refractory myocardial tissue, or anatomical/structural, e.g., a coronary vessel or a myocardial lesion; giving rise 
to functional and anatomical/structural reentry, respectively. The two main competing, but related, concepts of functional 
reentry are “leading circle reentry” and “spiral wave reentry”. For a comprehensive historical perspective on the 
development of the theoretical and experimental bases for our understanding of the different mechanisms of reentry, see 
(Jalife, 2010), which includes the major contributions from the laboratories of Moe, Allessie, Jalife, Haissaguerre, and 
others. 
 
2.1.1. Leading circle reentry 
In leading circle reentry, propagation is at the leading tip of a circuit located around a circle of critical dimensions, with 
wavelets emanating from that circle constantly maintaining the central core in a refractory state. The circumference of the 
circle, i.e., the minimum wavelength of the circuit, λ, is the effective refractory period (ERP) x conduction velocity (θ) 
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(Figure 1). For a reentrant circuit to exist, the wavelength must be shorter than the available conduction pathlength, thus 
leaving an excitable gap before the propagating wavefront. If atrial ERP or conduction velocity decrease, e.g., as a result 
of electrical remodelling, or if pathlength increases, e.g., from atrial hypertrophy or dilation, then the smaller wavelength 
relative to the pathlength will increase the chances of a re-entrant circuit, or multiple circuits, to exist and perpetuate. 
Furthermore, an increase in the spatial or temporal heterogeneity of electrical activity, e.g., resulting from localised 
interstitial fibrosis, or discordant alternans of the action potential duration (APD), will increase the likelihood of 
unidirectional conduction block and reentry (Figure 1). The ERP is determined by membrane excitability, i.e., the 
availability of Na+ channels to open and pass inward Na+ current (INa) and thus initiate the upstroke of an action potential. 
INa is voltage-dependent, and because it becomes available to open only after near full repolarisation of the preceding 
action potential, the ERP is largely determined by the APD at terminal repolarisation. In turn, this is determined by the 
magnitude and time course of repolarising K+ currents such as the ultra-rapid (IKur), rapid (IKr), and slow (IKS) delayed 
rectifier K+ currents, and inward rectifier K+ currents such as IK1 and the acetylcholine-activated K+ current (IKACh). 
Therefore, drugs which inhibit these K+ currents could inhibit or extinguish reentrant AF, by prolonging APD and ERP 
and thus increasing wavelength. For further detail on how inhibition of human atrial repolarising ion currents could affect 
the morphology and duration of the action potential, see illustrations in (Workman, 2010) and (Ravens, 2010). 
Myocardial conduction velocity is determined partly by the maximum rate of rise of the action potential upstroke, which 
is dependent on membrane excitability and INa magnitude. However, conduction velocity also depends largely on the 
degree of intercellular coupling, which depends on intercellular communication via gap junctions at the intercalated discs, 
and on the degree of any intercellular fibrosis. Therefore, myocardial diseases which reduce such coupling, and thus 
conduction velocity and wavelength, particularly in a spatially heterogeneous manner, could promote reentrant AF. 
Furthermore, drugs which reduce INa sufficiently to reduce conduction velocity should also be expected, by leading circle 
reentry, to promote reentrant AF. 
 
2.1.2. Anatomical/structural reentry 
For anatomical/structural reentry to occur, as with leading circle reentry, the wavelength of the reentrant circuit must be 
shorter than the available conduction pathlength. The conduction path is fixed, determined by the size of the 
anatomical/structural obstacle or feature and may be large, leaving a large excitable gap and producing regular and 
relatively slow-rate reentry. For example, in the most common form of the supraventricular arrhythmia, atrial flutter, in 
which reentry rate is typically ~300 beats/minute, the reentry circuit passes through a muscle isthmus adjacent to the 
tricuspid valve, the neighboring posterior right atrium, and the ostium of the coronary sinus (Gami et al., 2010). 
Anatomical/structural reentry may also be involved in both the generation and maintenance of AF.  
 
2.1.3. Spiral wave reentry 
In spiral wave reentry, curved activation wavefronts propagate outwards into excitable tissue in a spiral fashion, with 
their tips, which have the highest curvature, revolving around a central core (Figure 1). As with leading circle reentry, 
changes in ERP will tend to affect core size, but can also cause complex changes in wave tip trajectory that may lead to 
tip meandering and wave break up. Furthermore, the degree of curvature of the wave tip also affects core size. High 
curvature produces a small core, short excitable gaps and a high reentry rate, which manifests as a short AF cycle length 
(AFCL), the minimum interval between successive atrial electrogram deflections. The degree of curvature is determined 
by the strength of the wavefront “source” (INa) or “sink” (electrotonic influence of the resting cells). A reduction in INa 
reduces curvature, increasing core size and decreasing reentry rate, even when there is a full excitable gap, ultimately 
potentially blocking reentry. Conversely, reentry rate may increase when IK1 is increased, by an increase in electrotonic 
effects. Furthermore, an increase in ERP, e.g., by decreasing delayed rectifier K+ current, may cause a transition from a 
stable circular to a meandering spiral wave. Therefore, the effects of drugs which block, for example, Na+ or K+ channels, 
on reentrant mechanisms of AF are expected to differ according to which of the two models of reentry are considered to 
operate (Comtois et al., 2005). 
 
2.2. Non-reentry 
Non-reentrant mechanisms of arrhythmia include abnormal automaticity and triggered activity (Figure 1). Abnormal 
automaticity is the premature firing of action potentials due to accelerated diastolic depolarisation. This is favoured by 
an increase in diastolic inward, depolarising, ion currents such as the funny current (If), and also by a decrease in 
outward, hyperpolarising, currents such as the delayed rectifiers. Triggered activity is premature firing due to 
afterdepolarisations, which are either early (EAD), occurring during repolarisation, or delayed (DAD) until 
repolarisation is complete or nearly complete (Wit & Boyden, 2007). EADs are favoured by an increase in the APD 
that permits reactivation of ICaL, or by abnormalities in INa activation or inactivation. DADs (and also abnormal 
automaticity) are favoured by excessive increases in intracellular Ca2+ concentration. For example, β-adrenoceptor 
stimulation may increase the L-type Ca2+ current (ICaL) and the sarcoplasmic reticular Ca2+ content sufficiently to cause 
propagating waves of Ca2+-induced Ca2+ release via the ryanodine receptors (Eisner et al., 2009). This in turn may 
 3/37
cause DADs by activating a transient inward, depolarising, current carried by the Na+-Ca2+ exchanger (INa/Ca) as each 
extruded Ca2+ is exchanged with 3 Na+. Therefore, drugs which inhibit ion currents such as If and ICaL, or which 
antagonise β-adrenoceptors or suppress intracellular Ca2+ elevation, might be expected, in theory, to suppress non-
reentrant mechanisms of AF. 
[insert Figure 1] 
 
 
3. In-vivo models of AF used to investigate mechanisms of anti-arrhythmic drugs 
3.1. In-vivo model-types and clinical counterparts 
A wide variety of in-vivo models of AF has been used to study electrophysiological mechanisms of the development of 
this arrhythmia and, in most cases, to investigate the effects of drugs on such mechanisms. The interventions used 
generally mimic, as far as possible, clinical risk factors for AF (both established and potential). The major risk factors for 
AF are heart failure and a variety of associated or causative chronic myocardial diseases such as coronary artery disease, 
myocardial infarction, hypertrophy, hypertension, atrial dilation and valve disease (Camm et al., 2010). Each may cause 
chronic adaptational changes, “remodelling”, of atrial structure and function, and also neurohumoral imbalance. This may 
result in an “arrhythmogenic substrate”, an atrial myocardium predisposed to reentrant, or non-reentrant, electrical 
activity (Figure 1). Furthermore, once AF occurs, a persistence of the rapid atrial activation also causes atrial remodelling 
that promotes AF (Wijffels et al., 1995). Therefore, most of the animal models feature chronic interventions, of at least 2 
week’s duration. A predisposition to AF also may result from acute risk factors and stimuli (in the presence or absence of 
remodelling) such as elevated adrenergic and/or cholinergic stimulation, acute atrial dilation and stretch, and cardiac 
surgery. Therefore, acute models of AF have also been studied. All these chronic and acute models of AF, with the main 
atrial electrophysiological changes produced in each, are given in Table 1, along with comparative clinical data where 
available. Each intervention either produced spontaneous AF, eased the induction of AF by electrical stimuli (increased 
its “vulnerability”) or increased its duration before spontaneous reversion to sinus rhythm. 
[insert Table 1] 
 
3.1.1. Heart failure and myocardial infarction models of AF 
The most extensively studied heart failure model of AF is the dog chronic (2-6 week) ventricular tachypacing model, 
exemplified by studies from the Nattel laboratory (see (Li et al., 1999) and Table 1). This model reproduced the major 
haemodynamic, structural and biochemical changes which accompany human heart failure, e.g., left ventricular systolic 
dysfunction and hypertrophy, increased atrial pressure, dilation and interstitial fibrosis, atrial hypocontraction, and 
catecholamine elevation (Moe et al., 1989; Li et al., 1999; Stambler et al., 2003; Cha et al., 2004). It also remodelled 
atrial ion currents, decreasing transient outward K+ current (ITO), ICaL and IKS and increasing INa/Ca (Cha et al., 2004), but 
did not consistently change ERP, conduction velocity or AFCL in-vivo (Table 1). The fibrosis caused localised 
conduction-slowing and increased dispersion (spatial heterogeneity) of conduction velocity (Shinagawa et al., 2002c) 
which could promote reentry, especially in a dilated atrium, which would increase the available conduction pathlength 
(Figure 1). However, this model of heart failure could also produce non-reentrant atrial activity, since “spontaneous Ca2+ 
transient events” which may cause DADs were observed in-vitro (Yeh et al., 2008). Furthermore, localised, stable, high 
frequency foci were produced in right atrium and within or near the pulmonary veins (Fenelon et al., 2003; Ryu et al., 
2005). While those could be micro-reentrant, the finding that the 1st beat and mean cycle length of atrial tachycardia were 
directly related to the cycle length of the burst of stimuli that provoked the atrial tachycardia suggests that a triggered 
mechanism is more likely (Stambler et al., 2003). 
 Heart failure in patients was associated with a moderate increase or no change in atrial ERP in-vivo (Sanders et al., 
2003). However, a recent study in our laboratory showed that left ventricular systolic dysfunction in patients was 
independently associated with a reduction in the ERP of atrial cells in-vitro, with decreasing left ventricular ejection 
fraction correlating with ERP-shortening (Workman et al., 2009). Such ERP-decrease could promote reentry by 
decreasing wavelength. In support, evidence is emerging that a relatively longer duration of heart failure in dogs (16 
weeks ventricular tachypacing) may also decrease atrial ERP, both in-vivo (Table 1) and in-vitro (Sridhar et al., 2009). 
The type of AF-promoting atrial electrical remodelling may depend in part, therefore, on the duration of heart failure, 
with short duration perhaps favouring non-reentry, and long duration perhaps favouring reentry (Rankin & Workman, 
2009). However, the arrhythmia mechanism will also be influenced substantially by the degree of atrial structural 
remodelling, which is also time- as well as aetiology-dependent. There are few studies of atrial remodelling by 
ventricular myocardial infarction, a major cause of heart failure. In dogs, coronary artery ligation for 8 weeks had no 
effect on atrial ERP in-vivo (Table 1), although it caused APD-alternans, an increased APD-dispersion, a degeneration of 
activation into multiple wavelets, and a decreased conduction velocity. In rats, chronic myocardial infarction caused atrial 
fibrosis (Boixel et al., 2003). Preliminary data from our laboratory suggest that chronic myocardial infarction in rabbits 
causes atrial cellular hypertrophy and defects in atrial excitation-contraction coupling in the presence of β-adrenergic 
stimulation (Kettlewell et al., 2010). 
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3.1.2. Acute and chronic atrial dilation models of AF 
Acute and chronic atrial dilation has been investigated with a variety of species and interventions. Surgical disruption of 
tricuspid or mitral valves (Boyden & Hoffman, 1981; Verheule et al., 2003) caused chronic atrial volume overload from 
valvular regurgitation. Chronic atrial dilation was also produced by atrioventricular node ablation (Greiser et al., 2009) or 
with an arterio-venous shunt (Remes et al., 2008). Each model produced broadly similar atrial electrophysiological 
changes, so are grouped in Table 1 as “chronic atrial dilation”. The promotion of AF was accompanied by either 
increased or unchanged ERP, decreased or unchanged conduction velocity, and unchanged AFCL, from which it was 
suggested that the AF was not caused by wavelength-decrease in this model (Verheule et al., 2003). However, an increase 
in the available conduction pathlength from the dilation, perhaps coupled with fibrosis, inflammation and increased 
conduction velocity-dispersion (Verheule et al., 2003) could predispose to reentry, and atrial activation mapping 
demonstrated reentry in-vitro in the rabbit shunt model (Hirose et al., 2005). In patients, it is difficult to isolate effects of 
chronic atrial dilation from pathological covariables. Nevertheless, atrial enlargement was associated with an increase in 
atrial ERP (Chen et al., 1998), in line with some of the animal studies. Acute atrial dilation and stretch, precluding 
remodelling effects, were studied in-vivo, including in patients, using balloon catheters, volume-expanding solutions, or 
simultaneous-atrioventricular-pacing. Each intervention increased AF vulnerability, but effects on ERP were inconsistent 
(Table 1), including within species. However, ERP-dispersion was increased (Satoh & Zipes, 1996) and conduction 
velocity was decreased (Solti et al., 1989), both favouring reentry. In-vivo studies of hypertension-induced AF, e.g., 
following renal artery clamping are few (Table 1), and effects on ERP were variable, but a decreased conduction velocity 
and wavelength, and increased conduction velocity-dispersion (Lau et al., 2010), particularly in enlarged (Kistler et al., 
2006) or fibrosed (Kistler et al., 2006; Choisy et al., 2007) atria, could promote reentrant AF. 
 
3.1.3. Autonomic-imbalance models of AF 
Variations in autonomic tone profoundly influence the occurrence of AF, with increased cholinergic (vagal) or adrenergic 
(sympathetic) activity promoting AF. Cholinergic AF has been studied in-vivo by stimulating vagal nerves (Wang et al., 
1993; Hayashi et al., 1998; Fedorov et al., 2000; Hashimoto et al., 2006; Sarrazin et al., 2007), by using α-chloralose 
anaesthesia (David et al., 1990) or by delivering acetylcholine, carbachol or methylcholine intraatrially (Rensma et al., 
1988), intrapericardially (Kumar et al., 2009), intravenously (Vereckei et al., 2001; Everett et al., 2006), intraperitoneally 
(Kovoor et al., 2001) or topically (Niu et al., 2009). This invariably produced AF spontaneously or increased its 
vulnerability. Atrial ERP and wavelength were consistently and markedly decreased, with no effect on conduction 
velocity (Table 1). The mechanism of ERP-shortening is acceleration of terminal repolarisation as a result of cholinergic 
activation of IKACh. It is noteworthy that activation of agonist-independent (constitutively active) IKACh (Dobrev et al., 
2005) is considered to be a major determinant of atrial ERP-shortening associated with chronic AF in patients (see 
section 3.1.7). In dogs, a high dominant frequency of activation during cholinergic AF, measured by spectral analysis, 
indicated multiple high frequency zones (Everett et al., 2006). Focal, rapidly-firing, rotor-like electrograms were also 
recorded (Niu et al., 2009). An in-vitro study showed that the increase in atrial dominant frequency by acetylcholine 
likely depended both on acetylcholine concentration and IKACh magnitude (Sarmast et al., 2003). The arrhythmia 
mechanism has been mapped in-vivo in dogs, and macro-reentry resulting from unidirectional conduction block was 
demonstrated (Derakhchan et al., 2001). In patients, promotion of atrial reentry by cholinergic stimulation was suggested 
by effects of adenosine (which activates the same K+ channels as acetylcholine) to increase atrial dominant frequency; 
supported by mathematical modelling of effects of increasing IKACh on reentrant drivers (Atienza et al., 2006). Adrenergic 
stimulation, with intravenous isoprenaline, was studied in several species including human. AF vulnerability or incidence 
were consistently increased, but effects on other electrophysiological parameters were variable (Table 1). For example, in 
patients, isoprenaline caused a marked increase in conduction velocity and a small decrease in ERP, thus increasing 
wavelength (Shimizu et al., 1994), whereas in dogs, isoprenaline had no effect on wavelength (Rensma et al., 1988). 
Furthermore, adrenaline prolonged ERP in rabbit atria in-vitro (Smeets et al., 1986), whilst isoprenaline had no effect on 
ERP in human atrial isolated cells (Redpath et al., 2006). It is unclear whether adrenergic stimulation causes AF by 
reentry in-vivo, although isoprenaline sustained reentry in atrial/pulmonary vein tissues in-vitro (Arora et al., 2003). Non-
reentrant mechanisms are likely prominent, either from DADs or abnormal automaticity resulting from increased 
intracellular Ca2+ and consequent INa/Ca, primarily from stimulation of ICaL and A-kinase mediated phosphorylation of 
phospholamban (Workman, 2010). Simultaneous cholinergic/adrenergic discharges are common triggers of paroxysmal 
atrial tachycardia and paroxysmal AF, and the stimulation of ganglionic plexi (sites rich in cholinergic and adrenergic 
neurons) at the pulmonary vein-left atrial junction can facilitate the onset of these arrhythmias. The mechanism may 
involve the formation of afterdepolarisations as a result of intracellular Ca2+-elevation in the presence of APD-shortening 
(Chou & Chen, 2009). In a dog in-vivo model of AF (“local nerve-stimulation” in Table 1), high frequency electrical 
stimulation of the atrial surfaces might induce AF as a result of a simultaneous increase in cholinergic and adrenergic 
nerve activity. 
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3.1.4. Models of post-operative AF and atrial ischaemia 
AF is common after cardiac surgery, probably from multiple mechanisms such as autonomic imbalance, acute ischaemia, 
mechanical irritation, and pericarditis. Old age is a strong predictor of post-cardiac surgery AF, likely by conduction 
disturbances arising from increased atrial fibrosis, whereas pre-surgery atrial cellular electrophysiology probably is not 
(Workman et al., 2006). The sterile pericarditis model is an experimental counterpart to the patient post-cardiac surgery. 
It promotes AF, associated with decreased atrial ERP and conduction velocity (Table 1). The primary arrhythmia 
mechanism is probably reentry (Matsumoto et al., 2010), consistent with reduced wavelength and with functional lines of 
block due to conduction velocity-dispersion from altered gap junction distribution and/or fibrosis (Ryu et al., 2007). 
Acute atrial ischaemia was studied independently, by right coronary ligation in dogs. This invariably increased AF 
duration, and while effects on ERP were highly variable, conduction velocity always decreased (Table 1). Ischaemia also 
increased atrial conduction velocity-dispersion (Sakabe et al., 2008), impaired conduction between normally- and hypo-
perfused atrial myocardium (Shiroshita-Takeshita et al., 2007b), or impaired ERP rate-adaptation; the ability of 
increasing rate to shorten ERP (Jayachandran et al., 2000). These effects could promote reentry, but triggered activity 
from increased atrial intracellular Ca2+, e.g., from glycolytic inhibition (Ono et al., 2007), or from a rapid transient 
increase in APD, as shown in ventricle (Workman et al., 2000), should not be excluded. Chronic atrial infarction has also 
been studied, in dogs, by ligating the right intermediate atrial artery for 8 days (Table 1). This caused stable reentry 
circuits in the infarction border zone and increased the duration of burst pacing-induced AF, associated with increased 
conduction velocity-heterogeneity and fibrosis, and altered intracellular Ca2+-handling (Nishida et al., 2011). 
 
3.1.5. Transgenic mouse and other relevant models of AF 
Other in-vivo animal models of AF, most of which have been used to investigate anti-arrhythmic mechanisms of drugs, 
include hypercapnoea or transient asphyxia (relating to AF associated with sleep disordered breathing), hypoglycaemia, 
atrial mechanical injury (relating to conduction block from, e.g., scar, fibrosis), aconitine (“window” INa agonist)-induced 
triggered AF and a variety of transgenic mouse models (Table 1). Persistent conduction-slowing followed hypercapnoea-
reversal in sheep, and hypoglycaemia decreased ERP in dogs. The atrial injury models reliably produce reentry, e.g., 
around Y-shaped lesions (Jalil et al., 1997), and have been used extensively for pharmacological study. Genetically 
engineered over-expression of the ion channel protein Kir2.1 increased IK1 and decreased atrial ERP (Li et al., 2004); 
electrical changes commonly associated with human chronic AF (Workman et al., 2008). Under-expression (Zhang et al., 
2005) or knockout (Mancarella et al., 2008) of Cav1.3 or α1D, to decrease ICaL, increased AF vulnerability without 
changing ERP. KCNE1-knockout, which paradoxically increased IKS, increased AF incidence (Temple et al., 2005). 
Connexin40-knockout, to decrease gap junction-coupling, decreased conduction velocity; and Rac1 over-expression, to 
produce reactive O2 species and atrial fibrosis, also decreased conduction velocity (Reil et al., 2010). Altered ryanodine 
receptor function due to mutations (Chelu et al., 2009), or to knockout of an associated regulatory protein, FKBP12.6 
(Sood et al., 2008) promoted AF, likely by enhancing spontaneous diastolic sarcoplasmic reticular Ca2+ release. 
 
3.1.6. AF causes AF by electrical remodelling: chronic rapid atrial rate models 
AF normally occurs initially in short, self-terminating bouts, paroxysms, which may then become progressively longer. A 
persistence of the rapid atrial activation for several hours is sufficient in itself (i.e., in the absence of initial underlying 
pathology) to cause substantial AF-promoting atrial electrical remodelling. This was demonstrated first in goats , by the 
Allessie group: after 24 hr of burst pacing-induced AF, atrial ERP and wavelength were markedly decreased, and AF 
vulnerability was increased (Wijffels et al., 1995). Similar changes occur after AF-induction lasting 4 days-16 weeks 
(Table 1). Chronic atrial regular tachypacing, for 24 hr-18 weeks, produced similar electrical remodelling in other species 
(Table 1). The ERP-shortening occurred in left and right atria and pulmonary veins (Tang et al., 2006) and correlated 
with both atrial tachypacing duration (Lee et al., 2000) and AF vulnerability (Morillo et al., 1995). It also markedly 
decreased wavelength whether or not conduction velocity decreased (Table 1). Furthermore, chronic atrial tachypacing 
increased the dispersion of ERP (Fareh et al., 2001) and AFCL (Gaspo et al., 1997), and produced atrial hypertrophy and 
fibrosis (Zhao et al., 2010). Each of these promotes reentry, and multiple wavelet reentry was mapped in-vivo (Gaspo et 
al., 1997; Li et al., 2000). 
 
3.1.7. Clinical models of AF 
In patients, a history of chronic AF typically was associated with decreased atrial ERP in-vivo (Kojodjojo et al., 2007) 
and in-vitro (Workman et al., 2001), and decreased conduction velocity (Kojodjojo et al., 2007) and AFCL (Fujiki et al., 
2001). It was also associated with increased APD restitution slope (Kim et al., 2002), and with ERP-dispersion 
(Kojodjojo et al., 2007) and electrogram fractionation (Kumagai et al., 1991). The concordance between these and the 
AF/atrial tachypacing-induced changes in the animal models (Table 1) suggests that AF-induced atrial remodelling, 
probably promoting reentry, occurs in humans also. The ionic mechanisms of the ERP-shortening are probably primarily 
an increased IK1 and constitutively active IKACh, and altered intracellular Ca2+-handling, as identified in studies from 
several research groups, e.g. (Van Wagoner et al., 1997; Bosch et al., 1999; Workman et al., 2001; Dobrev et al., 2005) 
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and reviewed in (Workman et al., 2008). An increase in IKS might also be involved (Caballero et al., 2010). A decreased 
systolic intracellular Ca2+ transient, causing contractile dysfunction, may involve a loss of atrial T-tubules, in sheep 
(Lenaerts et al., 2009). Furthermore, an increase in diastolic sarcoplasmic reticular Ca2+ leak (Neef et al., 2010) and in 
“late” INa, (INaL) (Sossalla et al., 2010), both having the potential to cause afterdepolarisations, were associated with 
human chronic AF. However, it is unclear whether atrial remodelling from chronic AF or atrial tachypacing alters the 
propensity to afterdepolarisations. AF has been induced acutely in patients, using atrial tachypacing for necessarily brief 
periods (5-10 min). This caused reversible shortening of atrial ERP and AFCL (Table 1), which was dependent on 
tachypacing stimulus rate (Yu et al., 1998) and may have involved acute intracellular Ca2+-induced inactivation of ICaL, 
rather than the type of electrical remodelling that results from chronic AF. Nevertheless, this in-vivo model of acute AF 
has been used extensively to study electrophysiological mechanisms of anti-arrhythmic drugs. 
 
3.2. Model- and disease-dependence of arrhythmia mechanisms and potential drug effects 
Among the differing animal models of AF in section 3.1, and very likely, therefore, the clinical disease states they 
represent, there are wide variations in the atrial electrophysiological changes and mechanisms promoting this arrhythmia, 
as shown by Table 1. Anti-arrhythmic drugs that target reentrant or non-reentrant mechanisms may be expected, 
therefore, to affect AF differently depending on the disease state in question. Such drugs, either in clinical use or under 
investigation, have thus been tested in a variety of in-vivo models. 
 
 
4. Drug types for AF termination and prevention: conventional anti-arrhythmics; upstream therapy; 
investigational 
4.1. Pharmacological management of AF with Vaughan Williams class drugs 
Pharmacological treatment of patients with AF is aimed initially at protection against thromboembolic events, with anti-
coagulants. The focus is then either to restore sinus rhythm (rhythm control), or to limit the high ventricular rates 
resulting from the rapid atrial activation, by inhibiting atrioventricular nodal conduction (rate control). Rhythm control, 
with anti-arrhythmic drugs, is the long term goal in patients for whom rate control offers inadequate symptomatic relief, 
or in severely compromised patients (Camm et al., 2010). Anti-arrhythmic drugs are conventionally grouped according to 
their broad mechanism of action (Vaughan Williams, 1984), namely, Na+ channel blockade (class I), β-adrenoceptor 
antagonism (II), action potential prolonging (III), and Ca2+ channel blockade (IV). Many drugs that prevent AF possess 
activity in more than one class, and some in none. Nevertheless, this classification serves as a useful basis for assessing 
and comparing electrophysiological effects of drugs with broadly related activities in the various in-vivo models of AF. 
The current European Society of Cardiology guidelines for the management of AF (Camm et al., 2010) recommends the 
use of certain drugs from each of these classes for rhythm and/or rate control, depending on the patient’s disease state. 
 
4.2. Potential pharmacological management of AF with non-Vaughan Williams class drugs 
A variety of non-Vaughan Williams class drugs in clinical use, as well as some naturally occurring substances, can 
prevent or delay atrial structural remodelling associated with hypertension or heart failure. These “upstream therapies”, 
which include angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers, aldosterone 
antagonists, statins, and poly-unsaturated fatty acids, might deter new onset AF or its progression to permanent AF. Of 
these agents, the European Society of Cardiology recommends ACE inhibitors, angiotensin receptor blockers and statins 
to be considered for the treatment of AF, depending on disease state (Camm et al., 2010).  
 
4.3. Investigational drug types and rationale for development 
Numerous drugs tested in models of AF have either been approved for the treatment of cardiovascular diseases not 
including AF, or are currently under investigation for potential clinical use including for AF, or are intended purely for 
experimental use. These drugs are termed “investigational”. Recent development of drugs for rhythm control has 
focussed on “atrial-selective” and “multi-channel blocking” properties. Atrial-selectivity, in an attempt to avoid 
ventricular pro-arrhythmia, may be achieved, in theory, by targeting ion channels which occur in atrium and not ventricle 
(Ravens, 2010). Ion currents such as IKur and IKACh are generally accepted to contribute substantially to atrial, rather than 
to ventricular, repolarisation. Nevertheless, since IKur blockade may affect ventricular repolarisation in some species, e.g., 
dogs (Sridhar et al., 2007), IKur-inhibiting drugs perhaps should be considered as having “atrial-predominant” properties. 
A degree of atrial-selectivity may also be achieved by exploiting ion current characteristics such as availability or kinetics 
that differ between the chambers, either intrinsically or as a result of differing resting potential or activation rate during 
AF, e.g., those of INa (Burashnikov & Antzelevitch, 2010). Multi-channel blocker development is aimed primarily at 
mimicking the efficacious anti-arrhythmic effects of drugs with multiple actions such as amiodarone, but without their 
toxicity. Multi-channel blockers also may exhibit atrial-predominance. Other investigational drugs are aimed at 
improving intercellular coupling, e.g., gap junction-enhancers. 
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4.4. The need to assess and compare in-vivo mechanistic data on each drug type  
The vast majority of Vaughan Williams class drugs and upstream therapies currently recommended for the treatment of 
patients with AF has been studied extensively in in-vivo models of AF. Furthermore, investigational drugs, and many 
Vaughan Williams class drugs no longer in widespread use, as well as some drugs which have been withdrawn, were also 
tested in such models. To improve our overall understanding of anti-arrhythmic mechanisms of drugs having related, as 
well as unique actions, electrophysiological effects of drugs from all of these categories are examined in detail, below, 
where in-vivo mechanistic data are available.  
 
 
5. Class I drugs (Na+ channel blockers): in-vivo electrophysiological mechanisms of AF termination 
5.1. Sub classification of class 1 drugs, and clinical use in AF 
Class I drugs are divided into subclasses a, b and c, according to their effects on the ECG and ventricular conduction, 
APD and ERP (Vaughan Williams, 1984). The 1st available, quinidine, procainamide and disopyramide were designated 
Ia; lidocaine designated Ib. The subsequently developed class Ic drugs include flecainide, propafenone, pilsicainide and 
moricizine. Cibenzoline has class Ia and Ic activity. Of these drugs, the current European Society of Cardiology 
guidelines recommends that flecainide and propafenone can be used, in patients without coronary artery disease or heart 
failure, for converting short duration or recent onset AF, for reducing AF recurrence following cardioversion, and also for 
long term rhythm control (Camm et al., 2010). Quinidine is now rarely used owing to risk of ventricular pro-arrhythmia 
from prolongation of the QT interval, and disopyramide is also rarely used except for cholinergic AF (Camm et al., 
2010). 
 
5.2. Inhibition of leading circle reentry by class I drugs 
Atrial electrophysiological effects of each of these drugs has been studied in in-vivo models of AF. These effects are 
summarised in Table 2, from which several notable broad patterns emerge. 
[insert Table 2] 
 
In keeping with the main recognised action of class I drugs to block INa, the conduction velocity was reduced in the 
majority of studies, presumably by decreasing action potential maximum upstroke velocity. Most studies were in dogs, 
usually using cholinergic stimulation- or atrial injury-induced AF, and chronic AF/atrial tachypacing was studied in dogs 
and goats. The primary mechanism of AF in each of these models is reentry (see section 3.1). In cholinergic AF and 
chronic AF/atrial tachypacing, reentry was caused by a marked decrease in wavelength, from ERP-shortening with little 
or no concurrent change in conduction velocity (see Table 1). The chronic ventricular tachypacing model of heart failure, 
in which non-reentrant mechanisms may be more prominent, was not used. All class I drugs terminated AF, with varying 
efficacies, in most of the models and species studied, but tended not to decrease the vulnerability to its re-induction 
(Table 2). Also, all drugs, irrespective of model or species, increased AFCL where measured, without exception. The 
AFCL increase, in all the dog cholinergic AF studies, was associated with an increase in atrial ERP and wavelength 
(Table 2). This represents a partial or full reversal by the drugs of the decrease in ERP and wavelength which was caused 
by cholinergic stimulation, that was larger than the associated decrease in conduction velocity. Several class I drugs (e.g., 
flecainide, propafenone, quinidine) inhibit currents such as IKr or IKACh, in addition to INa. Such K+ current inhibition may 
be expected to increase atrial ERP and/or wavelength by increasing APD. However, inhibition of INa alone can also 
increase atrial ERP in the absence of an increase in APD, thus causing post-repolarisation refractoriness. For example, 
pilsicainide, which may block INa without also blocking K+ channels, produced post-repolarisation refractoriness in a dog 
model of cholinergic AF (Kanki et al., 1998). The effect of pilsicainide, and also of flecainide (Wang et al., 1992) and 
propafenone (Wang et al., 1993) was use-dependent, i.e., ERP was prolonged preferentially at high atrial rates, such as 
those encountered during AF. The mechanism of induction of post-repolarisation refractoriness likely involves a 
depression of INa reactivation and an increase in the diastolic threshold of excitation. Several INa blockers, particularly 
those with rapid unbinding kinetics, may produce post-repolarisation refractoriness in an atrial-predominant manner 
(Burashnikov & Antzelevitch, 2010). The effect of class I drugs to increase wavelength, by whatever ionic mechanism, in 
the canine cholinergic AF models is consistent with an anti-reentrant mechanism from an increase in wavelength beyond 
the available pathlength, according to the concept of leading circle reentry (Figure 1). Consistent with that, procainamide 
and propafenone (Wang et al., 1993), and flecainide (Wang et al., 1992) increased the size and decreased the number of 
reentry circuits in this model, and propafenone inhibited macro-reentry without affecting focal AF (Niu et al., 2009). In 
the non-cholinergic AF models, by contrast, no class 1 drug increased wavelength, and some even reduced it, e.g., 
flecainide and cibenzoline (Wijffels et al., 2000), despite increasing AFCL and terminating AF. This indicates that 
suppression of leading circle reentry may not be sufficient alone to explain anti-arrhythmic effects of INa blockers in these 
models. 
 
5.3. Inhibition of spiral wave reentry by INa blockade 
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An alternative explanation was provided using the goat model of chronic AF, and the concept of spiral wave reentry. 
Quinidine, cibenzoline and flecainide each were shown to increase not wavelength, but the “temporal excitable gap” 
(Wijffels et al., 2000). This was calculated as AFCL minus the ERP recorded during AF, the earliest moment at which a 
premature impulse could capture the fibrillating atrium (Figure 1). It was proposed that the increase in AFCL that 
widened the excitable gap was caused by a preferential slowing by the drugs of high-curvature wavefronts, due in turn to 
the reduction in the availability of the source current, INa. This should increase spiral wave reentry core size and decrease 
reentry rate, and allow wavelets to fuse and decrease in number, rather than fragment. In support, cibenzoline increased 
reentry wavelet “linking”, i.e., the number of consecutive waves propagating in the same direction, and decreased 
wavelet “fractionation” (Shan et al., 2004), in this model. Mathematical modelling supports the idea that inhibiting INa 
alone is sufficient to terminate AF by suppressing spiral wave reentry. Thus, a simulated reduction in INa increased the 
size of generator spirals and slowed their rotation rate by reducing excitability and conduction velocity, despite also 
decreasing wavelength (Nattel et al., 2003). Mathematical modelling has also highlighted the potential for atrial-selective 
termination of spiral wave reentry by INa inhibition (Pandit et al., 2010). The termination of AF by slowing spiral wave 
reentry is likely not exclusive to the AF/atrial tachypacing models of AF, since in an in-vitro study of cholinergic 
(acetylcholine-induced) AF, pilsicainide increased the reentry core perimeter associated with an increase in the temporal 
excitable gap, as well as increasing ERP (Kawase et al., 2003). Several class I drugs were studied in canine atrial injury 
models (Table 2) and, in each case, increased atrial ERP. Atrial wavelength was measured in one study, and was 
unchanged by quinidine, perhaps suggestive of suppression of spiral wave reentry. The only model in which AF was not 
terminated was atrial ischaemia. This intervention substantially decreases the conduction velocity (Table 1), and 
flecainide did not decrease it further (Table 2).  
 
5.4. Clinical mechanistic studies of class I drugs 
Atrial electrophysiological effects of several class I drugs were also studied in patients (Table 2). Where it was possible 
to measure the effect on ERP after conversion of brief episodes of induced AF (acute atrial tachypacing: shortens ERP 
and AFCL; Table 1), neither procainamide nor propafenone increased ERP, yet they decreased AF duration. Cibenzoline 
and flecainide increased AFCL and terminated AF. In one study (Brugada et al., 1993) atrial epicardial mapping was 
possible in one patient, and cibenzoline fused multiple reentry wavelets into a single broad wavefront. These clinical data 
are consistent with suppression of AF not involving long term atrial remodelling, potentially by inhibition of spiral wave 
reentry since ERP did not increase. By contrast, in patients with chronic AF (also associated with ERP- and AFCL-
shortening; Table 1), disopyramide, flecainide and propafenone increased atrial ERP. The ERP increase by flecainide was 
associated with APD increase and post-repolarisation refractoriness (Kirchhof et al., 2005). Procainamide, cibenzoline, 
flecainide and propafenone also increased AFCL (Table 2). Procainamide decreased the number of pulmonary vein 
ectopic beats (Chen et al., 1999), and a decrease in atrial electrogram fractionation was also observed in several studies 
(Brugada et al., 1993; Ishibashi et al., 1995; Tuan et al., 2010). Ιt is conceivable, therefore, that class I drug-induced ERP 
increase in patients with chronic AF could contribute to suppression of leading circle reentry. 
 
5.5. Potential suppression of non-reentrant arrhythmic activity by class I drugs 
Anti-arrhythmic effects of some class 1 drugs might involve a contribution from a suppression of non-reentrant 
arrhythmic activity. For example, in mouse ventricular cells in-vitro, flecainide reduced the incidence of isoprenaline-
stimulated triggered beats, associated with a reduction in the incidence of spontaneous Ca2+ release from the sarcoplasmic 
reticulum (Watanabe et al., 2009). However, such a mechanism has yet to be demonstrated in atrium. 
 
 
6. Class II drugs (β-blockers): electrophysiological mechanisms of AF suppression in-vivo 
6.1. Clinical use of β-blockers in AF 
Beta-adrenoceptor antagonists (β-blockers), such as the β1-blockers esmolol and metoprolol, and the β1/β2-blocker 
propranolol, currently are recommended mainly for rate control and for preventing post-cardiac surgery AF. Carvedilol, a 
β1/β2/α1-blocker, is also recommended for rate control. However, some β-blockers are also indicated for long term 
rhythm control, especially in exercise-induced AF (Camm et al., 2010). There are relatively few studies of atrial 
electrophysiological mechanisms of β-blockers pertaining to rhythm control using in-vivo models of AF; summarised in 
Table 3. 
[insert Table 3] 
 
6.2. Studies of acute β-blockade in models of atrial ERP-shortening and reentry 
β-blockers suppressed AF induced by a variety of interventions (Table 3). Their effects on atrial ERP, however, were 
reported in only 3 studies; of chronic AF in goats, acute atrial tachypacing in patients (both of which feature atrial ERP-
shortening; Table 1), and acute atrial ischaemia in dogs. In the goat study, propranolol was delivered either before or after 
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AF induction. It had no effect on ERP before AF, i.e., in the absence of atrial electrical remodelling; consistent with its 
lack of effect on ERP or conduction velocity in dogs in sinus rhythm (Rensma et al., 1988). Furthermore, its continuous 
delivery during the first 24 hr of AF did not prevent a marked AF-induced shortening of ERP and AFCL during that time 
(Wijffels et al., 1997). Moreover, when propranolol was administered acutely after AF had become persistent, i.e., after 
atrial remodelling, it did not reverse the effects of remodelling: ERP and AFCL were unchanged. Whether this drug 
affected AF vulnerability or duration was not stated. In the human study, propranolol again had no effect on atrial ERP 
before AF-induction, and also did not prevent ERP-shortening caused by the brief (~10 min) episode of induced AF. It is 
possible, therefore, that the anti-arrhythmic action of acute β-blockade in these models does not involve inhibition of 
reentry. However, data on conduction velocity and wavelength, and ultimately activation mapping during AF, are 
required to confirm that. By contrast, suppression of atrial ischaemia-induced AF, by the β1/β2-blocker nadolol, might 
involve inhibition of leading circle reentry, since it increased atrial ERP and conduction velocity (Table 3). 
 
6.3. Inhibition of non-reentrant activity by acute β-blockade 
In the local nerve-stimulation studies (Table 3), esmolol and propranolol decreased vulnerability to pulmonary vein 
repetitive focal activity and to atrial premature depolarisations. This could involve inhibition of abnormal automaticity, 
afterdepolarisations or reentry induced by combined adrenergic-cholinergic activation. A suppression of pulmonary vein 
electrical activity by propranolol was also reported in patients with paroxysmal AF (Chen et al., 1999). In-vitro studies of 
pulmonary vein/atrial preparations from dogs (Patterson et al., 2005) or rats (Doisne et al., 2009) suggest that β1-
blockade could suppress EADs or abnormal automaticity produced by local nerve stimulation or noradrenaline, 
respectively. Numerous studies, mainly in-vitro and reviewed in (Workman, 2010) indicate that β-blockers can prevent 
catecholamine-induced non-reentrant activity, mainly by inhibiting phosphorylation of proteins involved in intracellular 
Ca2+-handling including Ca2+ channels and phospholamban, and thus decreasing ICaL and excessive Ca2+-loading. 
Consistent with these studies, in chronic ventricular tachypacing-induced heart failure, which elevates circulating 
catecholamines (Moe et al., 1989) and promotes Ca2+-overload and DADs (Stambler et al., 2003), propranolol decreased 
AF vulnerability (Table 3).  
 
6.4. Pharmacological remodelling by chronic β-blockade 
A potential reentry-inhibiting mechanism of β-blockers is an atrial ERP-prolonging adaptation to their long-term use, so-
called pharmacological remodelling. This was demonstrated in rabbits in sinus rhythm, after 6 days of treatment with 
either a β1- or a β1/β2-blocker (Raine & Vaughan Williams, 1981), and also was independently associated with β1-blocker 
therapy in patients in sinus rhythm (Workman et al., 2003b; Workman, 2010). Among the studies in Table 3, β-blockers 
were probably given acutely in all but the chronic AF model (maximum 3-day treatment) and should not be expected, 
therefore, to have exerted their effects on AF by such pharmacological remodelling. While it is possible that a sufficiently 
long period of β-blockade to cause pharmacological remodelling still might not overcome ERP-shortening from AF-
induced electrical remodelling, the ERP increase in the absence of AF (Raine & Vaughan Williams, 1981; Workman et 
al., 2003b) could conceivably contribute to maintenance of sinus rhythm. 
 
 
7. Class III drugs (APD-prolonging): in-vivo electrophysiological mechanisms of AF termination and prevention  
7.1. Drug types, clinical uses in AF, and potential risks 
The original class III drug, amiodarone, is the most effective available anti-arrhythmic drug. It has multiple actions 
including inhibition of numerous ion currents (INa, ITO, ICaL, ICaT, IKur, IKr, IKS, IK,Na, INa/Ca, IK1, IKACh) and 
adrenergic/cholinergic receptors. Amiodarone is currently recommended for converting recent onset or persistent AF, for 
preventing AF recurrence, for long term rhythm control, and also for rate control when other measures are unsuccessful 
or contraindicated (Camm et al., 2010). However, amiodarone has serious side effects, and while it can be used in 
patients with structural heart disease, it may adversely affect nearly every organ. Dronedarone, its non-iodinated 
analogue, is safer but less efficacious (Piccini et al., 2009), and is recommended for long term rhythm and rate control in 
patients with non-permanent AF who don’t have severe or unstable heart failure. Other class III drugs such as dofetilide 
or ibutilide are recommended for converting AF or atrial flutter (Camm et al., 2010), but risk ventricular pro-arrhythmia, 
most likely from their inhibition of IKr. Sotalol is racemic, and the d-,l- form, used clinically and in most in-vivo models 
of AF, has both class III (IKr-blocking) and II (β1/β2-antagonising) action. It may be used for preventing AF recurrence, 
but is also limited by QT prolongation. Vernakalant, an IKur/INa/IKACh blocker, also has class III action and was recently 
recommended for approval by the European Medicines Agency for treating new onset AF (Camm et al., 2010). 
 
7.2. Suppression of leading circle reentry by class III effect 
Atrial electrophysiological effects of most of these drugs were studied in-vivo in animal models of a variety of causes and 
risk factors for AF. All drugs could terminate AF in one or more model, and generally increased atrial ERP and AFCL 
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(Table 4). The ERP increase often was associated with, and likely resulted from, prolongation of terminal repolarisation, 
e.g., of APD90 by amiodarone (Ashikaga et al., 2006) or ibutilide (Vereckei et al., 2001) in dogs, or by amiodarone 
(Pandozi et al., 2003) or sotalol (Kirchhof et al., 2005) in patients. The APD increase is generally ascribed to the effect of 
class III drugs to block atrial IKr. However, IKr exists also in ventricle, and ventricular APD increase, e.g., by dofetilide 
(Chandra et al., 2004), risks QT prolongation and ventricular pro-arryhythmia. The atrial ERP increase frequently was 
reverse use-dependent, i.e., stronger at low versus high rates (Nattel et al., 1998), one reason why class III drugs can fail 
to terminate AF yet can prevent its induction (Derakhchan et al., 2001). Class III drugs generally had little or no effect on 
atrial conduction velocity in animal models, but decreased it in patients with chronic AF, e.g., with amiodarone or 
ibutilide (Table 4). Atrial wavelength increased in most studies, always associated with ERP increase, suggestive of a 
general class III effect that could suppress leading circle reentry (Figure 1). In support, sotolol, which increased ERP and 
wavelength, also increased reentry circuit size and decreased their number, in cholinergic AF (Wang et al., 1993). 
Dofetilide, ibutilide and nifekalant also increased ERP and/or wavelength in that model (Table 4). 
[insert Table 4] 
 
7.3. Loss of class III effect in electrical remodelling 
There are exceptions to the rule of atrial ERP increase by class III drugs, however, particularly with the goat chronic AF 
model (Table 4). Thus, in all reports using this model, any drug effect to increase ERP either before AF or within the first 
24 hours of AF, was attenuated or lost subsequently, e.g., with amiodarone (Linz et al., 2007), dofetilide (Blaauw et al., 
2004), or ibutilide or sotalol (Duytschaever et al., 2005). Furthermore, in 2 studies, when ERP did not increase, neither 
did wavelength (Wijffels et al., 1999; Blaauw et al., 2004). Despite this, AFCL-increasing and anti-AF effects could 
persist (Wijffels et al., 1999; Linz et al., 2007). The reason for the loss of class III effect in the remodelled atria is 
unclear. However, it could be species-specific, since in dogs, both amiodarone and sotalol reversed chronic atrial 
tachypacing-induced AF and ERP-shortening when drug delivery was started after electrical remodelling (Shinagawa et 
al., 2003; Ashikaga et al., 2006; Sakamoto et al., 2009). Nevertheless, an attenuation of class III effect could occur in 
humans, since sotalol increased ERP less in patients with chronic AF than in those in sinus rhythm (Tse & Lau, 2002). 
 
7.4. Possible class III inhibition of spiral wave reentry 
Anti-arrhythmic, but non-ERP-prolonging, effects of class III drugs in the goat models suggest electrophysiological 
mechanisms other than inhibition of leading circle reentry. Termination of AF with increased AFCL, and not wavelength, 
by the class I drugs quinidine, cibenzoline and flecainide (Table 2), each of which may block IKr as well as INa, was 
considered due to inhibition of spiral wave reentry (see section 5.3). Such a mechanism is also possible for class III drugs 
(Figure 1). In support, d-sotalol (specific IKr blocker) had no effect on ERP or wavelength in the AF-remodelled atrium, 
yet terminated AF with an approximate doubling of the temporal excitable gap, an effect considered as potentially 
resulting from preferential slowing of high curvature reentry wavefronts (Wijffels et al., 2000). 
 
7.5. Clinical mechanistic and other studies of class III drugs 
Several class III drugs were studied in patients (Table 4). Amiodarone and sotalol decreased the incidence and duration of 
acutely-induced AF episodes, despite not inhibiting the ERP-shortening that these caused. However, in patients with 
chronic AF, which also shortens ERP, amiodarone increased ERP in all 4 studies, including in pulmonary vein (Rostock 
et al., 2005). AFCL was measured in 2 of those, and was increased in both. Ibutilide’s effect to terminate AF in patients 
was also accompanied by increased ERP, as well as decreased conduction velocity and increased AFCL. Sotalol 
increased ERP in each of 2 studies in patients with chronic AF, and also increased AFCL. Reports of class III drug 
studies using in-vivo models of AF that produce no clear atrial ERP-shortening (see Table 1), e.g., heart failure, atrial 
dilation, hypertension, adrenergic stimulation and atrial ischaemia, are relatively few (Table 4). In a single study using 
the dog ventricular tachypacing model of heart failure, dofetilide increased atrial ERP, wavelength and AFCL, with no 
change in conduction velocity, and blocked reentry and terminated AF (Li et al., 2000). In dogs with chronic atrial 
dilation, or atrial injury, dofetilide terminated AF, associated with increased ERP and AFCL and decreased conduction 
velocity, but it was unable to prevent ischaemia-induced AF. In a transient asphyxia model of AF, amiodarone or sotalol 
decreased AF vulnerability and duration, and amiodarone terminated aconitine-induced AF, presumably by inhibiting 
triggered activity. 
 
7.6. Recent drugs with class III action: dronedarone and vernakalant 
Dronedarone and vernakalant each have class III action, but data on their atrial electrophysiological mechanisms of 
action in in-vivo models of AF are lacking. Dronedarone (SR 33589), like amiodarone, inhibits INa in a frequency-
dependent manner, ICaL, various K+ currents, and β-adrenoceptors, and it may block IKACh more potently than amiodarone 
(Ravens, 2010). In dogs in sinus rhythm, intravenous dronedarone increased atrial and ventricular ERP (Manning et al., 
1995). A lack of change in ventricular ERP with decreased APD has also been reported (Verduyn et al., 1999). In dog 
atrial tissues in-vitro, acute dronedarone increased atrial ERP, but did not attenuate acetylcholine-induced ERP-
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shortening or AF. Acute amiodarone, by comparison, inhibited the ERP-shortening and AF (Burashnikov et al., 2010a). 
Dronedarone also suppressed dofetilide-induced EADs and ouabain-induced DADs in isolated Purkinje fibres (Varro et 
al., 2001). In patients with recurrent AF, dronedarone was superior to placebo in maintaining sinus rhythm, but 
electrophysiological mechanisms were not studied (Singh et al., 2007). Vernakalant increased atrial (and not ventricular) 
ERP in patients with no history of AF (Dorian et al., 2007). In patients with AF, vernakalant was efficacious in acutely 
terminating the arrhythmia, but atrial electrophysiological mechanisms were not studied (Roy et al., 2008). Vernakalant 
may be both atrial-predominant, since it blocks IKur/IKACh, and disease-specific, since it blocks INa preferentially at high 
rates and in depolarised tissue. Mathematical modelling suggested that rapidly-unbinding INa blockers such as vernakalant 
may terminate cholinergic AF, not by increasing atrial wavelength, but rather by decreasing atrial conduction velocity 
and spiral wave reentry rate, and destabilising “primary generator rotors” (Comtois et al., 2008). 
 
7.7. Pharmacological remodelling by amiodarone 
Another potentially anti-arrhythmic mechanism of a class III drug is pharmacological remodelling by amiodarone, 
perhaps analogous to that by chronic β-blockade (Workman, 2010). Thus, chronic (6 weeks) amiodarone treatment in 
dogs increased APD90 and ERP and caused post-repolarisation refractoriness, more so in isolated atrial than ventricular 
tissues, and inhibited acetylcholine-induced AF (Burashnikov et al., 2008). Increased pulmonary vein APD also was 
reported in this model (Sicouri et al., 2009), along with prevention of isoprenaline-induced DADs. 
 
 
8. Class IV drugs (Ca2+ channel blockers): electrophysiological effects in in-vivo models of AF 
8.1. Clinical use of Ca2+ channel blockers for rate control, and loss of effects on electrical remodelling 
The Ca2+ channel blockers verapamil and diltiazem are currently recommended for ventricular rate control (Camm et al., 
2010). However, their effects on atrial rhythm have also been studied, and in a wide range of in-vivo models of AF, along 
with those of other Ca2+ channel blockers: bepridil and efonidipine (Table 5). Ca2+ channel blockers prevented AF or 
inhibited its induction in 7 of 12 reports, but also could have no effect, or even promote AF (in 4 studies, each in a 
different model). Most studies were of verapamil and diltiazem, which block ICaL. The most consistent Ca2+ channel 
blocker effect was that of verapamil to increase atrial ERP in acute atrial tachypacing-induced AF in patients (Table 5). 
[insert Table 5] 
 
Thus, in each of 3 studies, verapamil, given just before an ~10 min episode of AF, attenuated or prevented AF-induced 
ERP-shortening. However, verapamil effects on AF were inconsistent, with either suppression (Daoud et al., 1997; Yu et 
al., 1998) or promotion (Sticherling et al., 2002). Abrupt increase in atrial rate, e.g., as occurs at the onset of an episode 
of AF in patients, rapidly elevates atrial intracellular Ca2+. By accelerating ICaL inactivation, this Ca2+ elevation may 
rapidly shorten ERP. A reduction in ICaL amplitude by verapamil could attenuate intracellular Ca2+ elevation, perhaps 
explaining its effect to attenuate such ERP-shortening in patients. Alternatively, inhibition of IKr (Zhang et al., 1999) 
and/or IKur (Gao et al., 2004) by verapamil might also contribute to the increase in ERP. Verapamil also increased ERP 
early on during atrial tachypacing in each of 2 studies using the dog chronic atrial tachypacing model (Table 5). An 
increase in wavelength (Ohashi et al., 2004) and a decrease in AF vulnerability (Lee et al., 2000) also were found. 
However, these effects of verapamil on ERP, wavelength and AF were lost after 1 or 2 weeks of continuous atrial 
tachypacing, despite daily drug administration. There was also a corresponding lack of effect of diltiazem on AF or atrial 
electrophysiology after 1 week of atrial tachypacing in this model (Table 5). One explanation for the time-dependent loss 
of effect of these drugs may be the fact that long term remodelling shortens ERP by different mechanisms than short term 
remodelling, e.g., by (potentially over-riding) increases in IK1 and IKACh (Workman et al., 2008). However, the ERP-
prolonging effect of efonidipine or bepridil, by contrast with that of verapamil, was not lost (Table 5). Both drugs block 
ICaT in addition to ICaL, and since a continuous inward leak of Ca2+ via ICaT may contribute to long term atrial remodelling 
(Fareh et al., 2001), the block of ICaT by these drugs might explain the persistence of their atrial electrophysiological/anti-
arrhythmic effects. 
 
8.2. Potential of Ca2+ channel blockers to inhibit non-reentrant AF 
Verapamil was also tested in the dog chronic (2-6 week) ventricular tachypacing model of heart failure which, by contrast 
with the chronic AF/atrial tachypacing models, does not shorten ERP (Table 1) and the AF it produces likely involves 
non-reentrant activity. In each of 2 studies (Table 5), verapamil could terminate AF. It had no consistent effect on AFCL 
(Stambler et al., 2003), and preferentially prevented AF due to atrial “drivers” rather than to “irregular activation” (Ryu 
et al., 2005). These data, contrasting with the relative lack of anti-AF action of ICaL blockade in the chronic AF/atrial 
tachypacing models, are in line with a suppression of non-reentrant atrial arrhythmic activity involving ICaL. Data are 
sparse on atrial electrophysiological mechanisms of Ca2+ channel blockers in most of the other models of AF studied, 
namely, cholinergic stimulation, atrial ischaemia, acute atrial dilation, and transient asphyxia (Table 5), and no consistent 
patterns emerged. Furthermore, AF was either promoted, inhibited or unchanged among these models. In patients with a 
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history of AF, atrial electrophysiological effects of Ca2+ channel blockers were studied only in those with paroxysmal AF. 
The ERP, wavelength and AFCL were not measured, and Ca2+ channel blocker effects on AF were inconsistent. Thus, 
verapamil either increased atrial dominant frequency, suggestive of a pro-arrhythmic effect by promoting high frequency 
zones of activation (Kushiyama et al., 2010), or decreased the incidence of pulmonary vein ectopic activity and “burst 
AF” (Chen et al., 1999).  
 
9. Upstream therapies and other clinically available agents: in-vivo mechanisms 
9.1. Atrial electrophysiological mechanisms of upstream therapies 
9.1.1. ACE inhibitors and angiotensin receptor blockers 
ACE inhibitors and angiotensin receptor blockers are currently recommended for consideration for primary prevention of 
AF in patients with heart failure and reduced left ventricular function, or with hypertension, and for secondary prevention 
in patients who have recurrent AF despite receiving anti-arrhythmic drugs (Camm et al., 2010). Several ACE inhibitors 
and angiotensin receptor blockers in clinical use have been studied in in-vivo models of AF, either chronic AF/atrial 
tachypacing or left ventricular dysfunction, in a variety of species (Table 6). 
[insert Table 6] 
 
These drugs were usually anti-arrhythmic, decreasing AF vulnerability, incidence or duration in 8 of 11 studies, 
irrespective of model type. With remarkable consistency, atrial ERP was unaffected by any ACE inhibitor or angiotensin 
receptor blocker in either model type. Candesartan also had no effect on the time course of chronic AF-induced 
shortening of ERP or AFCL (Hall et al., 2010). The duration of AF or atrial tachypacing in all of the chronic AF/atrial 
tachypacing studies (Table 6) was ≥1 week. However, it should be noted that, in a study of short term (3 hr) atrial 
tachypacing, either candesartan, or the ACE inhibitor captopril, prevented shortening of the atrial ERP (Nakashima et al., 
2000). ACE inhibitor/angiotensin receptor blocker effects on atrial global conduction velocity were less consistent, either 
leaving it unchanged or increasing it (Table 6). However, no ACE inhibitor or angiotensin receptor blocker decreased 
conduction velocity. When measured, atrial wavelength was unchanged, always coincident with a lack of change in 
conduction velocity (Table 6), but wavelength-increase may be expected in the 2 studies in which conduction velocity 
increased, since ERP was unchanged. An increase in wavelength could inhibit leading circle reentry. However, 
confirmatory activation mapping evidence with these drugs is lacking. Nevertheless, in the chronic ventricular 
tachypacing model, enalapril decreased atrial conduction velocity-dispersion, i.e., attenuated local conduction 
disturbances caused by heart failure (Li et al., 2001). Decreased electrical heterogeneity should oppose reentry, by 
preventing unidirectional conduction block (Figure 1). The improved conduction was associated with, and likely caused 
by, attenuation of heart failure-induced atrial fibrosis (Li et al., 2001). That was unlikely to have involved any effect of 
the drug to improve coronary flow, since fibrosis was unaffected by a non-ACE inhibitor vasodilator (Li et al., 2001). 
ACE inhibitors/angiotensin receptor blockers also inhibited pathological atrial structural remodelling in other studies in 
which they inhibited AF (Table 6), preventing fibrosis (Anne et al., 2007), myolysis (Li et al., 2007) and hypertrophy (Li 
et al., 2007). The reduction in fibrosis occurred whether with chronic atrial tachypacing or chronic ventricular 
tachypacing, despite atrial tachypacing producing substantially less fibrosis than ventricular tachypacing (Everett et al., 
2006). Consistent with this, ACE inhibitor therapy was associated with decreased atrial tissue collagen content in patients 
with chronic lone AF (Boldt et al., 2006). These effects on fibrosis and myolysis add support to an anti-arrhythmic 
mechanism involving improved conduction, and the atrial anti-hypertrophic action could also inhibit reentry by reducing 
the available pathlength (Figure 1). The biochemical mechanisms of increased atrial fibrosis in heart failure are 
incompletely understood, but likely involve induction of mitogen-activated protein kinases as a consequence of renin-
angiotensin-aldosterone system activation. The mechanism of suppression of atrial structural remodelling by the ACE 
inhibitors and angiotensin receptor blockers most likely involves, therefore, inhibition of pathological angiotensin 
elevation and associated signalling, as shown with enalapril in heart failure-induced AF (Li et al., 2001) and with 
quinapril and losartan in chronic atrial tachypacing-induced AF (Anne et al., 2007). Whether the anti-arrhythmic effects 
of ACE inhibitors and angiotensin receptor blockers involve a contribution from reversal of any acute pro-arrhythmic 
effects of angiotensin is unclear. Acute angiotensin had no effect on atrial conduction velocity, ERP or ERP-dispersion in 
patients (Kistler et al., 2005). In guinea pig atrial cells, acute angiotensin increased IKS and shortened APD (Zankov et al., 
2006). The contribution of IKS to human atrial repolarisation, however, may be relatively small (Workman, 2010). 
Nevertheless, acute angiotensin might produce EADs, by increasing the production of reactive O2 species, as shown in 
rabbit ventricular cells (Zhao et al., 2011). 
 
9.1.2. Aldosterone antagonists 
Aldosterone antagonists, e.g., spironolactone, may reduce AF recurrence in patients with hypertension and mild left 
ventricular dysfunction, but there is currently no recommendation regarding their use as upstream therapy in the 
prevention of AF (Camm et al., 2010). In the in-vivo models of AF, spironolactone or eplerenone decreased AF 
vulnerability either in heart failure or chronic atrial tachypacing (Table 6). Spironolactone also prevented atrial 
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tachypacing-induced atrial fibrosis, apoptosis and myolysis and the associated altered expression of regulatory proteins 
that could favour extracellular matrix degradation. This could improve local conduction and, coupled with the prevention 
by spironolactone of atrial hypertrophy (Zhao et al., 2010), might oppose reentry. 
 
9.1.3. Statins 
Statins are recommended for consideration for prevention of new-onset AF after cardiac surgery, or in patients with 
underlying heart disease, particularly heart failure (Camm et al., 2010). Several have been tested in representative animal 
models, which featured marked atrial fibrosis: pericarditis or heart failure in dogs, and reactive O2 species over-
production in mice. Chronic atrial tachypacing in dogs was also studied (Table 6). In all the dog studies, atorvastatin or 
simvastatin decreased AF duration and, in each case, increased either ERP, conduction velocity, or both, thus potentially 
increasing wavelength. However, in the transgenic mouse model, which produced atrial tachycardia rather than AF, 
rosuvastatin had no effect on ERP, conduction velocity or atrial tachycardia. The prevention by atorvastatin of 
pericarditis-induced decrease in ERP and conduction velocity is consistent with inhibition of atrial reentry, likely the 
primary arrhythmia mechanism in this model, and the improved conduction was coupled with decreased fibrosis. Atrial 
fibrosis and conduction velocity-dispersion were also prevented by simvastatin in the heart failure model. These data 
point to a contribution from anti-fibrosis to AF suppression by statins. However, numerous additional mechanisms may 
operate, e.g., improved lipid metabolism, altered membrane fluidity and ion channel conductance, and suppression of 
atherosclerosis, inflammation, reactive O2 species, endothelial dysfunction and neurohumoral activation (Savelieva et al., 
2010).  
 
9.1.4. Poly-unsaturated fatty acids 
There is presently no strong clinical evidence to support the use of n-3 (omega-3; fish oil-derived) poly-unsaturated fatty 
acids in primary or secondary prevention of AF, as discussed in the current guidelines (Camm et al., 2010) and 
corroborated by a subsequent randomised double-blind, placebo-controlled clinical trial (Kowey et al., 2010). Among a 
variety of in-vivo animal models, n-3 poly-unsaturated fatty acids either suppressed AF or had no effect, and also exerted 
minimal effect on atrial electrophysiology (Table 6). Nevertheless, in the 2 dog ventricular tachypacing models, which 
cause localised atrial conduction disturbances, poly-unsaturated fatty acids reduced atrial conduction velocity-dispersion. 
In one study, atrial fibrosis was also reduced (Sakabe et al., 2007). Again, such structural effects could oppose reentry. 
Non-reentry should not be excluded, however, since poly-unsaturated fatty acids inhibited afterdepolarisations in 
ventricular cells from patients with heart failure, coupled with a lowering of intracellular Ca2+ (Den Ruijter et al., 2008). 
Other putative anti-AF mechanisms of poly-unsaturated fatty acids include plasmalemma stabilisation, vasodilation, and 
modulation of ion channels or gap junctions. Poly-unsaturated fatty acids may also suppress inflammation, as a result of 
activation of peroxisome proliferator-activated receptors, and suppress reactive O2 species production (Savelieva et al., 
2010). 
 
9.1.5. Other potential upstream therapies 
Fenofibrate and pioglitazone, activators of peroxisome proliferator-activated receptor-α and -γ, respectively, were studied 
in heart failure models (Table 6). Only pioglitazone suppressed AF, which was associated with increased conduction 
velocity, likely from a suppression of atrial fibrosis. The anti-inflammatory drugs prednisone and ibuprofen were studied 
in a chronic atrial tachypacing model of AF (Table 6). Prednisone decreased AF vulnerability and duration and increased 
ERP, while ibuprofen had no effect. The anti-oxidant vitamin C was also tested, in 2 studies of chronic atrial tachypacing 
(Table 6). In the 1st, it attenuated atrial ERP-shortening, but AF was not studied. In the 2nd, vitamin C had no effect on 
ERP-shortening or AF. 
 
9.2. Atrial electrophysiological mechanisms of digoxin in rate and rhythm control 
Digoxin is neither a Vaughan Williams class drug nor upstream therapy. It is a Na+,K+ pump blocker, recommended for 
rate control at rest (due to its vagotonic effect) (Camm et al., 2010). This drug was studied in a goat chronic AF model, to 
assess its potential to affect mechanisms of rhythm control and atrial remodelling. Digoxin either moderately increased 
AF vulnerability and duration, or had no effect (Table 6). It had no effect on atrial ERP, conduction velocity, AFCL or 
electrogram fractionation (Duytschaever et al., 2000). Such a lack of effect of Na+,K+ pump blockade on atrial 
electrophysiology in this model is consistent with the reported absence of change in atrial Na+,K+ pump current density in 
patients with chronic AF (Workman et al., 2003a). However, digoxin delayed ERP-recovery after cessation of AF in 
goats, perhaps by a persistent effect to elevate intracellular Ca2+ (Tieleman et al., 1999). Such an effect could 
theoretically increase AF recurrence in patients after cardioversion. In line with this, digoxin exacerbated AF re-induction 
and atrial ERP-shortening following acute atrial tachypacing-induced AF in patients (Table 6). It was noted that, because 
all patients underwent autonomic blockade (Sticherling et al., 2000), the AF-promoting effect of digoxin was more likely 
due to its effect to increase intracellular Ca2+ than to increase vagal tone. 
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10. Investigational anti-arrhythmic drugs: in-vivo electrophysiological mechanisms of AF termination and 
prevention 
10.1. Types of investigational drugs and AF models studied 
Numerous investigational drugs have been studied in in-vivo animal models of AF (Table 7). Many are being tested as 
potential treatments for AF, and some have already been approved for other conditions. Others were withdrawn, or are 
intended purely for experimental use. Most studies were in dogs, usually in ERP-shortening, reentry-promoting, models: 
chronic AF/atrial tachypacing or cholinergic stimulation. Reentry-promoting atrial injury models were also widely used. 
Relatively few drugs were tested in models of atrial structural remodelling, such as heart failure or pericarditis. This may 
reflect the primary mechanism of action of most drugs tested: APD-prolonging ion channel blockers. The relatively 
selective blockers are shown first in Table 7, followed by multi-channel blockers, then gap junction-enhancers and others.  
 
10.2. Investigational ion channel blockers: in-vivo electrophysiological mechanisms 
The ion channel blockers as a group increased atrial ERP with remarkable consistency: in 23 of 25 studies in which it was 
measured (Table 7). Atrial wavelength was increased in 5 of 6 studies, always as a result of ERP-increase, and AFCL was 
also consistently increased: in 19 of 20 studies. These drugs tended to terminate AF more effectively than inhibit its 
induction. 
 
10.2.1. Selective ion channel blockers 
Of the selective ion channel blockers, three: DPO-1 (a diphenylphosphine oxide), NIP-151 (a benzopyrane derivative) 
and tertiapin (a bee venom peptide) target IKur or IKACh and are thus atrial-predominant. In line, AF-termination by each 
was accompanied by an increase in atrial ERP without effect on ventricular ERP. This is desirable as it minimises 
ventricular pro-arrhythmia risk from ventricular afterdepolarisations. The likely anti-AF mechanism was suppression of 
reentry by the ERP increase. However, NIP-151 and tertiapin also terminated aconitine-induced AF (Table 7), 
presumably by suppressing afterdepolarisations. The selective IKr blockers all terminated AF and prolonged atrial ERP, 
except for almokalant. However, several also prolonged the QT interval and/or ventricular ERP: e.g., almokalant, KCB-
328 and MK499. The anti-arrhythmic mechanism presumably involved suppression of reentry, the predominant 
arrhythmia mechanism in the models used. In support, KCB-328 also decreased ERP-dispersion (Rahme et al., 2001), 
potentially inhibiting unidirectional conduction block (Figure 1). Atrial flutter was mapped during azimilide (IKr/IKS 
blocker) treatment in the chronic atrial dilation model. Azimilide terminated this arrhythmia by increasing ERP and 
preferentially decreasing conduction velocity in slowly-conducting zones of atrial reentry circuits (Restivo et al., 2001). It 
should be noted, however, that since the electrophysiological mechanisms of atrial flutter may differ from those of AF 
(see section 2.1.2), the effects of azimilide on these arrhythmias also may differ. Azimilide also increased ERP in the 
cholinergic AF model, terminating AF when AFCL-increase was greatest. Selective IKs blockade with HMR 1556 also 
terminated AF, including in pigs (Table 7). However, it increased ventricular as well as atrial ERP (Nakashima et al., 
2004). The aminobenzimidazole NS8593 blocks the small conductance Ca2+-activated K+ current (ISKCa). An increase in 
ISKCa may contribute to APD-shortening from rapid atrial pacing (Ozgen et al., 2007). In an in-vivo rat model, NS8593 
decreased AF duration (Table 7) associated with, and considered to be caused by, increased ERP as measured in-vitro in 
the same study. NS8593 did not prolong the QT interval, in guinea pig hearts (Diness et al., 2010). The Na+-H+ 
exchanger current (INa/H) inhibitor cariporide (HOE642) did not affect atrial electrophysiology in a chronic atrial 
tachypacing model (Table 7). Nevertheless, it prevented atrial ERP-shortening and loss of ERP rate-adaptation due to 
atrial ischaemia, both effects which could oppose reentry. However, it is presently unclear whether atrial INa/H is altered in 
AF-remodelling (Workman et al., 2008). 
[insert Table 7] 
 
10.2.2. Multi-channel blockers 
All the multi-channel blockers (Table 7) inhibit at least one K+ current (most commonly IKr), and over half block INa. 
Those that block IKur and/or IKACh may possess some degree of atrial-predominance: ambasilide, AVE0118, AZD7009, 
nibentan, NIP-142, SD-3212, SSR149744C, and tedisamil. Furthermore, those which block INa with marked voltage-
dependence also may be atrial-predominant, by producing greater block in atrium than ventricle, e.g., ranolazine (anti-
anginal), AZD7009, and possibly SSR149744C (celivarone; structural analogue of amiodarone). Additional block of INaL, 
e.g., with ranolazine (Sossalla et al., 2010), could also counterbalance any ventricular APD-prolonging effect of IKr block 
and thus potentially lower pro-arrhythmic risk. For detailed ionic mechanisms of such atrial-predominance, refer to 
(Ravens, 2010). Most multi-channel blockers terminated AF (Table 7). All except vanoxerine (dopamine transporter 
antagonist) increased ERP, likely by increasing atrial APD, e.g., AVE0118 (Blaauw et al., 2007) and SD-3212. 
AVE0118 (a biphenyl derivative) did not affect QT (Blaauw et al., 2007), consistent with atrial-selectivity. By contrast, 
ambasilide, AZD7009, nibentan, ranolazine and tedisamil all could increase QT and/or ventricular ERP. Furthermore, the 
effects of AVE0118 were not lost as electrical remodelling progressed (Linz et al., 2007), unlike those of, for example, 
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the IKr blockers d-sotalol and ibutilide (see section 7.3). AVE0118 also attenuated an increase in both ventricular 
repolarisation-heterogeneity and fibrillation caused by ventricular ischaemia in dogs (Billman & Kukielka, 2008). In 
Table 7, the consistently increased atrial ERP (and wavelength where measured) suggest an effect of the multi-channel 
blockers to inhibit leading circle reentry (Figure 1), as considered in the study of AVE0118 (Blaauw et al., 2004). 
Supporting evidence was provided by mapping: ambasilide (Wang et al., 1994) and nibentan (Fedorov et al., 2000) 
terminated AF by decreasing the number and increasing the size of co-existing reentrant circuits required to support AF. 
However, some INa-blocking drugs might inhibit spiral wave reentry (see section 5.3): AZD7009 terminated pericarditis-
induced AF by slowing conduction at wavefront “pivot points” (Goldstein et al., 2004), and vanoxerine reduced the 
“safety factor for conduction” in slow zones of reentry circuits (Matsumoto et al., 2010). Ranolazine’s anti-arrhythmic 
mechanism was not determined, and an effect to reduce atrial dominant frequency was considered as due to its inhibition 
of either macro-reentry or focal atrial tachycardia (Kumar et al., 2009). In support of an anti-reentrant mechanism, 
ranolazine increased atrial ERP and post-repolarisation refractoriness (without affecting ventricular ERP) in dog atria in-
vitro (Sicouri et al., 2010). However, ranolazine could also suppress triggered activity, as demonstrated in dog pulmonary 
veins in-vitro (Sicouri et al., 2008), perhaps by its inhibition of INaL; an effect potentiated in cells isolated from patients 
with chronic AF (Sossalla et al., 2010). Data are emerging on a synergism between effects of ranolazine and other anti-
arrhythmic drugs. In atrial tissues isolated from dogs treated chronically with amiodarone, acute ranolazine produced a 
synergistic, use-dependent and atrium-predominant depression of INa-dependent action potential parameters, and 
abolished acetylcholine plus burst pacing-induced AF (Sicouri et al., 2010). Furthermore, acute ranolazine plus acute 
dronedarone produced post-repolarisation refractoriness in dog atrial tissues, in a synergistic, use-dependent and atrial-
predominant manner. This drug combination also markedly reduced the incidence of acetylcholine-induced AF, and of 
isoprenaline plus high extracellular Ca2+-induced DADs and triggered activity in isolated pulmonary vein sleeves 
(Burashnikov et al., 2010b). 
 
10.3. Gap junction-enhancers 
Gap junction-enhancing peptides were tested in a wide range of animal models (Table 7), most of which reduce atrial 
conduction velocity (see Table 1) and/or increase its dispersion (see section 3.1). Uncoupling of atrial cells by interstitial 
fibrosis is a prominent feature of some of these models, e.g., ventricular tachypacing-induced heart failure, and 
pericarditis. However, the contribution to uncoupling from gap junction remodelling in those, or in chronic AF/atrial 
tachypacing models, is unclear. By contrast, loss of gap junction communication in acute ischaemia is considered to 
contribute substantially to conduction-slowing and arrhythmogenesis. GAP-134 (small molecule gap junction-modifier) 
and rotigaptide (stable derivative of the anti-arrhythmic peptide AAP10) increased atrial conduction velocity and did not 
affect atrial ERP in all in-vivo studies (Table 7). However, any consequent increase in wavelength generally was 
accompanied by disparate effects on AF: rotigaptide was ineffective in chronic ventricular tachypacing or atrial 
tachypacing, and GAP-134 suppressed AF in the ventricular tachypacing plus atrial tachypacing model only in animals 
with minimal atrial dilation. Furthermore, GAP-134 increased atrial dominant frequency and electrogram disorganisation 
(Laurent et al., 2009), consistent with AF promotion, rather than inhibition. However, in atrial ischaemia or pericarditis, 
gap junction-enhancers suppressed AF (Table 7). The anti-AF mechanism in ischaemia may have been due in part to the 
decrease in conduction velocity-dispersion, an effect not produced by rotigaptide in the heart failure model, in which AF 
was not inhibited. The biochemical mechanism of the enhanced gap junction communication likely involved enhanced 
phosphorylation and/or suppressed dephosphorylation of connexins (Shiroshita-Takeshita et al., 2007b). 
 
10.4. Other investigational drugs 
Other investigational drugs include those that affect intracellular Ca2+-handling: mibefradil (withdrawn from clinical use), 
K201 (JTV-519), ryanodine and tetracaine (local anaesthetic); as well as an anti-fibrotic and a 5-hydroxytryptamine 
antagonist (Table 7). Mibefradil, an ICaT blocker, decreased the duration of chronic atrial tachypacing-induced AF in 
dogs, associated with an increase in atrial ERP and a decrease in its dispersion (it prevented atrial tachypacing-induced 
ERP-remodelling), without changing conduction velocity, and consequently increased wavelength. The anti-arrhythmic 
mechanism may have involved an attenuation of intracellular Ca2+ elevation-induced atrial remodelling, by block of 
inward Ca2+ leak via ICaT which, unlike ICaL, is not downregulated in atrial tachypacing-remodelling (Yue et al., 1997). 
K201 (benzothiazepine derivative) has multiple actions: inhibition of INa, ICaL and various K+ channels, and stabilisation 
of ryanodine receptor conformation which may reduce a potentially arrhythmogenic diastolic sarcoplasmic reticular Ca2+ 
leak. In-vivo, K201 suppressed AF, associated with an increase in atrial ERP, and with no change in conduction velocity 
(Table 7). It also prolonged the QT interval, however. The anti-AF mechanism was considered to be inhibition of reentry, 
the likely predominant cause of AF in the pericarditis model. In support, K201 decreased the vulnerability to carbachol-
induced AF in guinea pig hearts in-vitro, associated with atrial ERP-increase, likely from an observed inhibition of IKACh 
and IKr (Nakaya et al., 2000). However, K201 could also suppress non-reentrant AF since it reduced DAD amplitude or 
the rate of spontaneous activity, associated with a decreased intracellular Ca2+ transient and INa/Ca, in rabbit pulmonary 
vein isolated cells (Chen et al., 2008). Furthermore, K201 attenuated diastolic spontaneous sarcoplasmic reticular Ca2+ 
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release caused by intracellular Ca2+ elevation in rabbit ventricular cells (Loughrey et al., 2007). The ryanodine receptor 
inhibitor ryanodine terminated atrial tachycardia after increasing its cycle length in a heart failure model of AF (Table 7). 
The anti-arrhythmic mechanism is unknown, but since this drug inhibits sarcoplasmic reticular Ca2+ release and this 
model produces spontaneous atrial depolarisations (Stambler et al., 2003), a suppression of non-reentrant activity is 
possible. Tetracaine, which also inhibits ryanodine receptors, suppressed AF in a transgenic mouse model (Table 7). An 
associated reduction in the incidence of spontaneous sarcoplasmic reticular Ca2+ release events in atrial cells (Sood et al., 
2008) again suggests suppression of non-reentrant activity. However, an anti-reentrant contribution from INa blockade 
should not be excluded. The anti-fibrotic, pirfenidone, attenuated heart failure-induced atrial conduction-slowing in dogs, 
in line with an observed attenuation of fibrogenesis and associated cytokine disruption, and did not affect ERP (Table 7). 
It also attenuated conduction velocity-dispersion which, by reducing electrical heterogeneity, could inhibit reentry. 
Finally, the 5-hydroxytryptamine4 antagonist RS-100302 terminated AF in a pig model. This was associated with an 
increase in atrial wavelength from increased ERP with minimal conduction-slowing, and with no change in ventricular 
ERP or QT. The increased wavelength, coupled with decreased ERP-dispersion, could inhibit reentry, the main 
mechanism of AF in this model. However, suppression of non-reentrant activity should not be excluded since, in human 
atrial isolated cells, another 5-hydroxytryptamine4 antagonist, GR-113808, suppressed “cellular arrhythmic 
depolarisations”, which may represent abnormal automaticity or afterdepolarisations (Pau et al., 2007). 
 
 
11. Concluding remarks and future directions 
An overview of these data on in-vivo electrophysiological mechanisms of pharmacological termination and prevention of 
AF, as represented in Figure 1, allows several conclusions to be drawn. Studies of effects of class I drugs suggest that Na+ 
channel blockade per se can terminate AF by decreasing atrial conduction velocity and slowing spiral wave reentry. Any 
effect of these drugs to increase atrial ERP, including from concurrent block of K+ channels, and particularly in disease 
states that shorten the ERP, should contribute to AF termination by increasing wavelength. From the limited available 
data on effects of class II drugs in in-vivo models of AF, the mechanisms by which acute β-blockade suppresses AF are 
rather unclear. However, numerous in-vitro studies suggest a prominent contribution from inhibition of atrial pro-
arrhythmic effects of catecholamines, likely involving a reduction in non-reentrant mechanisms by limiting excessive 
Ca2+ influx. This is in line with clinical effects of these drugs to suppress AF associated with elevated adrenergic tone. 
The chronic use of β-blockers may provide an additional, potentially anti-reentrant action, by an adaptive prolongation of 
the atrial ERP; so called pharmacological remodelling. Class III drugs may block IKr only or multiple ion currents, but a 
general effect of inhibiting atrial reentry by increasing atrial ERP is likely their main anti-arrhythmic mechanism, in a 
variety of disease settings. However, a diminution or loss of class III effect of some of these drugs may occur as a result 
of electrical remodelling. Furthermore, many of the class III drugs risk ventricular pro-arrhythmia. Mechanistic data on 
the influence of class IV drugs on AF suggest that any beneficial effect of the rate-controlling Ca2+ channel blockers on 
atrial rhythm during AF may be lost as a result of electrical remodelling. Limited data suggest that Ca2+ channel blockers 
might be more effective in suppressing heart failure-induced AF, possibly by inhibiting non-reentrant mechanisms. 
However, these drugs cannot be used in patients with heart failure because of their ventricular negative inotropic effects. 
The main atrial anti-arrhythmic mechanism of most of the upstream therapies was a potentially reentry-inhibiting 
improvement in atrial conduction resulting from inhibition of atrial fibrosis and myocyte degradation, rather than from 
any substantial effects on repolarisation. Thus, in heart failure models of AF, which feature prominent atrial structural 
remodelling, ACE inhibitors, statins and poly-unsaturated fatty acids each decreased atrial conduction-heterogeneity. The 
predominant atrial anti-arrhythmic mechanism of many investigational ion channel blockers was probably suppression of 
leading circle reentry, by an increase in ERP and wavelength, without a decrease in conduction velocity. However, 
inhibition of spiral wave reentry and/or non-reentry likely contributed in some cases. Many of these drugs increased the 
QT interval and thus risked ventricular pro-arrhythmia. However, some were relatively atrial-, and also potentially 
disease-, selective, and did not prolong QT. Gap junction-enhancers tended to improve atrial conduction, but were only 
moderately effective in preventing AF. A multitude of actions of some investigational drugs, including atrial-
predominant modulation of multiple ion channels, autonomic receptors, and intracellular Ca2+-handling, likely 
contributed to their anti-AF effects in highly complex, pathology-dependent ways. 
 It may be noted that extensive investigation of in-vivo mechanistic electrophysiological effects of drugs in different 
models of AF seems not to be a requirement for their approval for the treatment of patients with AF, e.g., for the recently 
approved dronedarone, or the first available class III drug, amiodarone. However, as highlighted by this review, such 
investigations have demonstrated that the efficacy of drugs to suppress AF may be quite different in different disease 
states underlying the arrhythmia, and at different time points during the progression of electrical and structural 
remodelling. Perhaps future drug-testing may focus more on models of AF that produce marked atrial structural as well 
as electrical remodelling (and not necessarily primarily in dogs, e.g., see Table 7), including for ion channel blockers, i.e. 
non-upstream therapies. Studies of ventricular tissue have highlighted temporal heterogeneities of APD and restitution as 
pro-arrhythmic, particularly those resulting from alternating changes (alternans) of APD and the systolic intracellular 
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Ca2+ transient. Such alternans could be pro-arrhythmic in atrium also (Blatter et al., 2003), but this will require further 
investigation, including in-vivo. Current theories concerning the cellular mechanisms of alternans infer a pathological 
disruption of sarcoplasmic reticular function; the prevention of which could provide a novel route for pharmacological 
intervention independent of classic ion channel blockade. The study of mechanisms of atrial-predominant, multiple-
action drugs in development, as well as of currently available drugs, in in-vivo models of AF should help inform about 
patient groups most likely to benefit from such treatments, and potentially about appropriate timing of differing drug 
therapy-types during the progression of AF, as the predominating arrhythmia mechanisms change. Furthermore, as 
mathematical models of atrial electrophysiology incorporate increasingly realistic anatomical and functional parameters 
relating to the development of AF, these should also help inform about potential electro-pharmacological mechanisms of 
AF termination and prevention. 
 It is hoped that the study of electrophysiological mechanisms of acute and chronic effects of anti-arrhythmic drugs in 
a variety of types of in-vivo, and in-vitro, models of AF, aided by mathematical modelling, will improve our 
understanding of how we might increase the efficacy and safety of pharmacological treatments for preventing AF in 
patients. 
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[Figure legend] 
Figure 1 
Overview of in-vivo electrophysiological mechanisms of AF and their pharmacological termination or 
prevention. Diagram shows main reentrant and non-reentrant arrhythmia mechanisms predisposing to 
(constituting a “substrate” for) AF, along with the drug types which inhibit them. λ=reentry circuit wavelength; 
ERP=effective refractory period; θ=conduction velocity; EG=excitable gap; AFCL=AF cycle length; 
AA=abnormal automaticity; EAD=early afterdepolarisation; DAD=delayed afterdepolarisation; TA=triggered 
activity; class I-IV=Vaughan Williams class of anti-arrhythmic drug; UT=upstream therapy; ID=investigational 
anti-arrhythmic drug; “?”=potential drug action or non-reentrant mechanism: requires confirmation in-vivo 
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[Tables, with legends] 
Table 1 
In-vivo animal models and clinical studies of AF used, or not used* for drug investigations, showing pathology-
induced changes in atrial electrophysiology  
 
In-vivo model 
/clinical study 
Species AF ERP θ λ CL Refs 
Ventricular MI* Dog ?inc/dur ? ?   Miyauchi et al., 2003 
HF: VTP 16wk* Dog ?dur ?    Sridhar et al., 2009 
HF: VTP 2-6wk Sheep, 
dog, rabbit 
?vul/inc 
/dur 
?/? ?/? ? ?/? Power et al., 1998; Li et al., 1999; Shinagawa et al., 2002c; Stambler et al., 2003; 
Cha et al., 2004; Shroff et al., 2006; Shimano et al., 2008; Laurent et al., 2008b 
HF: VTP+ATP Dog ?/?vul 
/?dur 
?/? ?   Shinagawa et al., 2002a; Shinagawa et al., 2002c; Laurent et al., 2008a; 
Ramadeen et al., 2010 
LVH Mouse ?vul ?    Zhang et al., 2006 
Clinical HF* Human ?vul ?/? ?   Sanders et al., 2003 
Chronic atrial 
dilation 
Goat, sheep 
dog 
?vul/?inc 
/?dur 
?/? ?/?  ? Boyden & Hoffman, 1981; Restivo et al., 2001; Verheule et al., 2003; Deroubaix 
et al., 2004; Neuberger et al., 2005; Remes et al., 2008; Greiser et al., 2009 
Clinical atrial dil.* Human  ?    Chen et al., 1998 
Acute atrial dil. Human 
goat, dog 
?vul ?/?/? ?  ? Solti et al., 1989; Satoh & Zipes, 1996; Wijffels et al., 1997; Tse et al., 2001 
Hypertension* Sheep ?vul/dur ?/? ? ?  Kistler et al., 2006; Lau et al., 2010 
Cholinergic-stim. Dog, mouse ?vul/inc ? ? ?  Rensma et al., 1988; Hayashi et al., 1998; Fedorov et al., 2000; Kovoor et al., 
2001; Sarrazin et al., 2007 
Adrenergic-stim.* Human, dog, 
mouse 
?vul/inc ?/? ?/? ?/? ? Rensma et al., 1988; Shimizu et al., 1994; Stambler et al., 1996; Kiss et al., 
2004; Sampson et al., 2008 
Local nerve-stim. Dog ?inc ?    Schauerte et al., 2001 
Pericarditis Dog ?vul/dur ? ?   Kumagai et al., 2004; Ryu et al., 2007 
Atrial ischaemia Dog ?dur  ?/?/? ?  ? Jayachandran et al., 2000; Rivard et al., 2007; Sakabe et al., 2008 
Atrial infarction* Dog ?vul/?dur  ?    Nishida et al., 2011 
Hypercapnoea-
reversal* 
Sheep ?vul ? ?   Stevenson et al., 2010 
Asphyxia Rat ?vul/dur     Haugan et al., 2004; Diness et al., 2010 
Hypoglycaemia* Dog ?vul ?    Vardas et al., 1993 
Atrial injury Dog ?vul     Feld & Shahandeh-Rad, 1992; Jalil et al., 1997 
Aconitine Dog, cat ?inc     Winslow, 1981; Hashimoto et al., 2006 
?/? ion channel* T-mouse ?vul/inc ?/?    Li et al., 2004; Temple et al., 2005; Zhang et al., 2005; Mancarella et al., 2008 
?connexin* T-mouse ?vul  ?   Hagendorff et al., 1999 
?ROS/fibrosis/inflam. T-mouse ?vul/inc ?/? ?   Sawaya et al., 2007; Reil et al., 2010 
?/?Ca2+i protein T-mouse ?vul ? ?   Sood et al., 2008; Chelu et al., 2009 
Chronic AF Pig, goat ?vul/dur ? ? ? ?/? Wijffels et al., 1995; Bauer et al., 2005; Eijsbouts et al., 2006; Greiser et al., 2009 
Chronic ATP Sheep, dog ?vul/?/?inc 
/?dur 
? ?/? ? ? Morillo et al., 1995; Gaspo et al., 1997; Li et al., 1999; Fareh et al., 2001; Tang et 
al., 2006; Anne et al., 2007; Nakashima & Kumagai, 2007; Lenaerts et al., 2009; 
Zhao et al., 2010 
Clinical AF Human  ? ?  ? Kumagai et al., 1991; Fujiki et al., 2001; Kim et al., 2002; Kojodjojo et al., 2007 
Acute ATP Human ?inc ?   ? Yu et al., 1998; Biffi et al., 1999; Sticherling et al., 2000 
Arrows show reported direction of change in atrial fibrillation (AF) vulnerability (vul), incidence (inc) and 
duration (dur); atrial effective refractory period (ERP), conduction velocity (θ) and reentry wavelength (λ); 
and AF cycle length (CL), in various animal models of AF, relative to a pre-intervention control; or 
associated with the presence of a clinical disease; from selected representative references. MI=myocardial 
infarction; HF=heart failure; VTP=ventricular tachypacing; ATP=atrial tachypacing; LVH=left ventricular 
hypertrophy; T-mouse=transgenic mouse; ROS=reactive O2 species; Ca2+i=intracellular Ca2+; Acute 
ATP=atrial tachypacing-induced brief (5-10min) episodes of AF in patients 
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Table 2 
In-vivo effects of class I anti-arrhythmic drugs (Na+ channel blockers) on AF and atrial electrophysiology in 
animal models or clinical studies of AF  
 
Drug 
Class I 
In-vivo model 
/clinical study 
Species AF ERP θ λ CL Refs 
Cibenzoline Chronic AF Goat Term/?vul ? ? ?/? ? Wijffels et al., 1999; Wijffels et al., 2000; Shan et 
al., 2004; Eijsbouts et al., 2006 
 Acute ATP Human Term    ? Brugada et al., 1993 
 Clinical AF Human Term    ? Brugada et al., 1993; Fujiki et al., 2001 
Disopyramide Atrial injury Dog Term ?   ? Inoue et al., 1991 
 Clinical AF Human ?vul ? ?   Ishibashi et al., 1995 
Flecainide Cholinergic-stim. Dog Term/?dur ? ? ? ? Wang et al., 1992; Rivard et al., 2007 
 Atrial ischaemia Dog ?dur ? ?  ? Rivard et al., 2007 
 Asphyxia Rat ?dur/?vul     Haugan et al., 2004 
 Chronic AF/ATP Goat, dog Term/ 
?vul/dur 
?/? ?/? ?/? ? Wijffels et al., 1999; Wijffels et al., 2000; 
Shinagawa et al., 2003; Duytschaever et al., 2005; 
Eijsbouts et al., 2006 
 Acute ATP Human Term    ? Biffi et al., 1999 
 Clinical AF Human Term ?   ? Kirchhof et al., 2005; Tuan et al., 2010 
Lidocaine Cholinergic-stim. Dog Term     David et al., 1990 
Moricizine Pericarditis Dog Term ? ?  ? Ortiz et al., 1994 
Pilsicainide Cholinergic-stim. Dog Term ? ? ? ? Hayashi et al., 1998; Kanki et al., 1998; 
Shinagawa et al., 2000 
Procainamide Cholinergic-stim. Dog Term/?inc ? ? ? ? Wang et al., 1993; Vereckei et al., 2001 
 Atrial injury Dog  ?   ? Derakhchan et al., 1994; Jalil et al., 1997 
 Acute ATP Human ?inc/dur ?    Yu et al., 1998 
 Clinical AF Human Term    ? Fujiki et al., 2001 
Propafenone Cholinergic-stim. Dog Term/?inc 
/?dur 
? ? ? ? Wang et al., 1993; Niu et al., 2009 
 Atrial injury Dog Term ?   ? Inoue et al., 1991; Derakhchan et al., 1994 
 Chronic ATP Dog Term ? ?  ? Chandra et al., 2004 
 Acute ATP Human Term/?inc/dur ?   ? Yu et al., 1998; Biffi et al., 1999 
 Clinical AF Human Term ? ?  ? Tai et al., 1998 
Quinidine Atrial injury Dog Term ? ? ? ? Cha et al., 1996 
 Chronic AF Goat Term/?vul ?/? ?/? ? ? Wijffels et al., 1999; Wijffels et al., 2000 
Term=acute termination of AF after drug administration. See legend of Table 1 for other definitions 
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Table 3 
In-vivo effects of class II anti-arrhythmic drugs (β-blockers) on AF and atrial electrophysiology in animal 
models or clinical studies of AF 
 
Drug 
Class II 
In-vivo model 
/clinical study 
Species AF ERP θ λ CL Refs 
Esmolol Local nerve-stim. Dog ?vul     Schauerte et al., 2001 
Nadolol Cholinergic-stim. Dog ?dur     Rivard et al., 2007 
 Atrial ischaemia Dog ?inc/dur ? ?  ? Rivard et al., 2007 
Propranolol HF: VTP 2-6wk Dog ?vul     Stambler et al., 2003 
 Local nerve-stim. Dog ?vul     Schauerte et al., 2001 
 Asphyxia Rat ?vul/?dur     Haugan et al., 2004 
 Chronic AF Goat  ?   ? Wijffels et al., 1997 
 Acute ATP Human ?inc/dur ?    Yu et al., 1998 
See legend of Table 1 for definitions 
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Table 4 
In-vivo effects of class III (action potential-prolonging) anti-arrhythmic drugs on AF and atrial electrophysiology 
in animal models or clinical studies of AF 
 
Drug 
class III 
In-vivo model 
/clinical study 
Species AF ERP θ λ CL Refs 
Amiodarone Cholinergic-stim. Dog ?vul     Huang et al., 2006 
 Asphyxia Rat ?vul/dur     Haugan et al., 2004; Diness et al., 2010 
 Aconitine Cat Term     Winslow, 1981 
 Chronic AF/ATP Goat, dog Term/?vul/ 
inc/dur 
?/? ?/?  ? Shinagawa et al., 2003; Ashikaga et al., 2006; 
Linz et al., 2007 
 Acute ATP Human ?inc/dur ?    Yu et al., 1998 
 Clinical AF Human Term ? ?/?  ? Tai et al., 1998; Pandozi et al., 2003; Maury & 
Zimmermann, 2004; Rostock et al., 2005 
Dofetilide HF: VTP 2-6wk Dog Term/?vul/dur ? ? ? ? Li et al., 2000 
 Chronic atrial dil. Dog Term/?vul ? ?  ? Restivo et al., 2001 
 Cholinergic-stim. Dog Term/?term 
/?vul/?dur 
? ? ? ? Nattel et al., 1998; Derakhchan et al., 2001; 
Rivard et al., 2007 
 Atrial ischaemia Dog ?dur ? ?  ? Rivard et al., 2007 
 Atrial injury Dog Term ? ? ? ? Cha et al., 1996 
 Chronic AF/ATP Goat, dog ?Term/?vul 
/dur 
?/? ? ?/
? 
? Li et al., 2000; Shinagawa et al., 2003; Blaauw 
et al., 2004; Chandra et al., 2004; Linz et al., 
2007 
Ibutilide Cholinergic-stim. Dog Term ?    Vereckei et al., 2001 
 Atrial injury Dog Term ?    Stump et al., 2005 
 Chronic AF/ATP Goat, dog ?Term/?vul 
/dur 
?/? ? ? ? Blaauw et al., 2004; Vereckei et al., 2004; 
Duytschaever et al., 2005 
 Acute ATP Human Term ?   ? Sticherling et al., 2002 
 Clinical AF Human Term ? ?  ? Tai et al., 1998 
Nifekalant Cholinergic-stim. Dog Term ? ? ? ? Hayashi et al., 1998 
 Chronic ATP Dog ?vul/dur ? ? ?  Tang et al., 2006 
 Clinical AF Human  ? ?   Minami et al., 2004 
Sotalol Cholinergic-stim. Dog ?Term/Term/ 
?vul/?vul 
? ? ? ? Wang et al., 1993; Wang et al., 1994; 
Derakhchan et al., 2001 
 Asphyxia Rat ?vul/dur     Haugan et al., 2004 
 Chronic AF/ATP Goat, dog Term/?vul/dur 
/?vul/dur 
?/? ? ? ? Wijffels et al., 1999; Wijffels et al., 2000; 
Duytschaever et al., 2005; Sakamoto et al., 
2009 
 Acute ATP Human ?inc/dur ?    Yu et al., 1998 
 Clinical AF Human ?vul ?   ? Tse & Lau, 2002; Kirchhof et al., 2005 
See legend of Table 1 for definitions 
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Table 5 
In-vivo effects of class IV anti-arrhythmic drugs (Ca2+ channel blockers) on AF and atrial electrophysiology in 
animal models or clinical studies of AF 
 
Drug 
class IV 
In-vivo model 
/clinical study 
Species AF ERP θ λ CL Refs 
Bepridil Chronic ATP Dog ?vul/dur ?   ? Nishida et al., 2007 
Diltiazem Cholinergic-stim. Dog ?inc/dur     Rivard et al., 2007 
 Atrial ischaemia Dog ?inc/dur ? ?  ? Rivard et al., 2007 
 Chronic ATP Dog ?dur ? ? ?  Fareh et al., 2001 
Efonidipine Chronic ATP Dog  ? ? ?  Ohashi et al., 2004 
Verapamil HF: VTP 2-6wk Dog Term/?term/?vul     Stambler et al., 2003; Ryu et al., 2005 
 Acute atrial dil. Human ?vul ?    Tse et al., 2001 
 Asphyxia Rat ?vul/?dur     Haugan et al., 2004 
 Chronic AF Goat ?dur ? ?  ? Duytschaever et al., 2000 
 Chronic ATP Dog ?vul/?vul/dur/?dur ?/? ? ?/?  Lee et al., 2000; Ohashi et al., 2004 
 Acute ATP Human ?Term/?vul/inc/dur/?dur ?   ? Daoud et al., 1997; Yu et al., 1998; Sticherling et al., 2002 
See legend of Table 1 for definitions 
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Table 6 
In-vivo effects of upstream therapies & other clinically-available non-Vaughan Williams class agents on AF and 
atrial electrophysiology in animal models of AF 
 
Agent In-vivo model Species AF ERP θ λ CL Refs 
Cilazapril: ACEI Chronic ATP Dog ?vul/dur     Li et al., 2007 
Enalapril: ACEI HF: VTP 2-6wk Dog ?dur ?  ? ?  Li et al., 2001 
 Chronic ATP Dog ?vul/dur ? ? ?  Shinagawa et al., 2002b 
Quinapril: ACEI Chronic ATP Sheep ?inc ? ? ?  Anne et al., 2007 
Candesartan: ARB HF: VTP 2-6wk Rabbit ?dur ? ?   Shimano et al., 2008 
 LVH Mouse ?vul ?    Zhang et al., 2006 
 Chronic AF/ATP Goat, dog ?vul/dur/?dur ? ?  ? Kumagai et al., 2003b; Hall et al., 2010 
Losartan: ARB Chronic ATP Sheep ?inc ? ? ?  Anne et al., 2007 
Olmesartan: ARB Chronic ATP Dog ?dur ? ?   Nakashima & Kumagai, 2007 
Valsartan: ARB Chronic ATP Dog ?vul/dur     Li et al., 2007 
Eplerenone: A-A HF: VTP 2-6wk Dog ?vul ? ?   Shroff et al., 2006 
Spironolactone: A-A Chronic ATP Dog ?vul/dur     Zhao et al., 2010 
Atorvastatin: statin Pericarditis Dog ?dur ? ?   Kumagai et al., 2004 
Rosuvastatin: statin ?ROS/fibrosis T-mouse ?inc ? ?   Reil et al., 2010 
Simvastatin: statin HF: VTP 2-6wk Dog ?dur ? ?   Shiroshita-Takeshita et al., 2007a 
 Chronic ATP Dog ?vul/dur ?    Shiroshita-Takeshita et al., 2004 
PUFA HF: VTP 2-6wk Dog ?vul/?dur ? ?   Sakabe et al., 2007 
 HF: VTP+ATP Dog ?vul/dur ? ?   Laurent et al., 2008a 
 Cholinergic-stim. Dog ?vul ?    Sarrazin et al., 2007 
 Chronic ATP Dog ?vul/dur ? ?   Sakabe et al., 2007 
Fenofibrate: PPAR-α? HF: VTP 2-6wk Dog ?dur ? ?   Shiroshita-Takeshita et al., 2007a 
Pioglitazone: PPAR-γ? HF: VTP 2-6wk Rabbit ?dur ? ?   Shimano et al., 2008 
Prednisone: A-I Chronic ATP Dog ?vul/dur ?    Shiroshita-Takeshita et al., 2006 
Ibuprofen: A-I Chronic ATP Dog ?vul/dur ?    Shiroshita-Takeshita et al., 2006 
Vitamin C Chronic ATP Dog ?vul/dur ?/?    Carnes et al., 2001; Shiroshita-Takeshita et al., 2004 
Digoxin: glycoside Chronic AF Goat ?vul/dur/?dur ? ?  ? Tieleman et al., 1999; Duytschaever et al., 2000 
 Acute ATP Human ?inc ?    Sticherling et al., 2000 
ACEI=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; A-A=aldosterone 
receptor antagonist; PUFA=poly-unsaturated fatty acid; PPAR=peroxisome proliferator-activated receptor; 
A-I=anti-inflammatory; See legend of Table 1 for other definitions 
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Table 7 
In-vivo effects of investigational anti-arrhythmic drugs on AF and atrial electrophysiology in animal models of 
AF 
Investigational drug In-vivo model Species AF ERP θ λ CL Refs 
DPO-1: ?IKur Atrial injury Dog Term ?    Stump et al., 2005 
Almokalant: ?IKr Chronic AF Goat ?Term    ? Santos et al., 2008 
E-4031: ?IKr Atrial injury Dog Term ?   ? Inoue et al., 1991 
KCB-328: ?IKr Atrial injury Dog Term ? ? ? ? Rahme et al., 2001 
 Chronic ATP Dog Term ? ?  ? Chandra et al., 2004 
MK499: ?IKr Atrial injury Dog Term ?    Stump et al., 2005 
Azimilide: ?IKr/IKs Chronic atrial dil. Dog Term/?vul ? ?  ? Restivo et al., 2001 
 Cholinergic-stim. Dog Term ? ?  ? Nattel et al., 1998 
HMR 1556: ?IKs Cholinergic-stim. Dog ?dur ?   ? Nakashima et al., 2004 
 Chronic AF Pig Term     Bauer et al., 2005 
NS8593: ?ISKCa Asphyxia Rat ?dur     Diness et al., 2010 
NIP-151: ?IKACh Cholinergic-stim. Dog Term ?    Hashimoto et al., 2008 
 Aconitine Dog Term     Hashimoto et al., 2008 
Tertiapin: ?IKACh Cholinergic-stim. Dog Term ? ?   Hashimoto et al., 2006 
 Aconitine Dog Term/?dur     Hashimoto et al., 2006 
Cariporide: ?INa/H Atrial ischaemia Dog  ?    Jayachandran et al., 2000 
 Chronic ATP Dog ?vul/dur ? ? ?  Shinagawa et al., 2002b 
Ambasilide: ?ITO/IKur/INa/IKr/IKs Cholinergic-stim. Dog Term/?inc ? ? ? ? Wang et al., 1994 
 Pericarditis Dog ?inc ? ? ?  Wang et al., 1994 
AVE0118: ?IKur/ITO/IKACh Chronic AF Goat Term/?vul ? ? ? ? Blaauw et al., 2004; Blaauw et al., 2007; Linz et al., 
2007 
AZD7009: ?IKr/INa/ITO/IKur Pericarditis Dog Term/?vul ? ?  ? Goldstein et al., 2004 
Nibentan: ?IK/IKACh Cholinergic-stim. Dog Term/?vul ? ? ? ? Fedorov et al., 2000 
NIP-142: ?IKACh/IKur/IKs/IKr/ITO/ICaL/ICaT Cholinergic-stim. Dog Term/?vul ? ?  ? Nagasawa et al., 2002 
 Atrial injury Dog Term/?vul    ? Nagasawa et al., 2002 
Ranolazine: ?IKr/IKS/INa/INaL Cholinergic-stim. Pig ?vul/dur ? ?   Kumar et al., 2009 
SD-3212: ?INa/ICaL/IK/IKACh Atrial injury Dog Term ? ?  ? Fujiki et al., 1997 
SSR149744C: ?INa/ICaL/IKur/IKr/IKS/ 
IKACh, α-/β-/angiotensin receptors 
Cholinergic-stim. Dog Term/?vul ?   ? Gautier et al., 2005 
Tedisamil: ?ITO/IKur/IKr/IKs/IKATP Cholinergic-stim. Dog Term    ? Fischbach et al., 2001 
 Atrial injury Dog Term/?vul ? ?  ? Fischbach et al., 1999 
 Chronic ATP Dog Term/?vul    ? Fischbach et al., 2001 
Vanoxerine: ?IKr/ICaL/INa Pericarditis Dog Term ? ?  ? Matsumoto et al., 2010 
AAP10: ?Igap Asphyxia Rat ?vul/dur     Haugan et al., 2004 
GAP-134: ?Igap HF: VTP+ATP Dog ?vul/dur/ 
?vul/dur 
? ? ?  Laurent et al., 2009 
 Pericarditis Dog ?vul/dur ? ?   Rossman et al., 2009 
Rotigaptide: ?Igap HF: VTP 2-6wk Dog ?vul/dur ? ?   Shiroshita-Takeshita et al., 2007b 
 Atrial ischaemia Dog ?dur ? ?   Shiroshita-Takeshita et al., 2007b 
 Chronic ATP Dog ?vul/dur ? ?   Shiroshita-Takeshita et al., 2007b 
Mibefradil: ?ICaT Chronic ATP Dog ?dur ? ? ?  Fareh et al., 2001 
K201: ?Ca2+i/INa/ICaL/IKACh/IKr/IK1 Pericarditis Dog ?vul/?dur ? ?  ? Kumagai et al., 2003a 
Ryanodine: RyR inhibitor HF: VTP 2-6wk Dog Term/?vul    ? Stambler et al., 2003 
Tetracaine: ?INa/IK1/Ca2+i ?Ca2+i protein T-mouse ?vul ?    Sood et al., 2008 
Pirfenidone: ?fibrosis HF: VTP 2-6wk Dog ?dur ? ?   Lee et al., 2006 
RS-100302: 5-HT4 antagonist Atrial injury Pig Term/?vul ? ? ? ? Rahme et al., 1999 
See text for definitions of ion currents. Ca2+i=intracellular Ca2+; RyR=ryanodine receptor; 5-HT=5-
hydroxytryptamine 
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